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ABSTRACT OF DISSERTATION 
 
 
NEUROINFLAMMATION IN ALZHEIMER’S DISEASE AND VASCULAR 
COGNITIVE IMPAIRMENT 
 
It was once believed that the brain was immunologically privileged with no 
resident or infiltrating immune cells; however, now it is understood that the cells 
of the brain are capable of a wide range of inflammatory processes and 
phenotypes. Inflammation in the brain has been implicated in several disease 
processes such as Alzheimer’s disease (AD) and vascular cognitive impairment 
and dementia (VCID); however, the role of inflammation in these two dementias 
is poorly understood. 
 When we stimulated a pro-inflammatory phenotype with an adeno-
associated viral vector in a transgenic mouse model of AD that develops Aβ 
plaques, we saw a pro-inflammatory response at 4 months that transitioned to a 
mixed phenotype by 6 months. This transition also appeared with an increase in 
Aβ burden suggesting that anti-inflammatory markers contribute to disease 
progression.  
 Treatment of astrocytes, microglia, endothelial cells and neurons with high 
levels of homocysteine, a risk factor for VCID, resulted in a wide range of gene 
expression changes. Astrocytes showed decreased levels of several potassium 
channels and aquaporin 4 and increased matrix metalloproteinase 9. Microglia 
showed an initial pro-inflammatory response that transitioned to an anti-
inflammatory phenotype. Endothelial cells showed a disruption in several tight 
junction proteins and neurons had changes in kinases and phosphatases known 
to affect tau phosphorylation. 
 Finally, while AD and VCID are the two most common forms of dementia, 
they are not mutually exclusive and it is estimated that 60% of AD patients also 
have cerebrovascular pathology contributing to the clinical syndrome. To 
determine the effect of co-morbid AD and VCID on the effectiveness of therapies 
that target AD pathologies, we placed APP/PS1 mice on a diet that induces 
hyperhomocysteinemia and consequently VCID. These mice were then placed 
on an anti-Aβ immunotherapy. While the co-morbidity mice had a  
significant reduction in Aβ, there was no cognitive benefit of the immunotherapy 
in these mice. Interestingly, these co-morbidity mice also had a reduction in 
inflammatory markers and microglial staining, suggesting a suppressed 
inflammatory response. From these studies, it is clear that inflammation plays a 
complex role in AD, VCID and during treatment when both AD and VCID are 
present. 
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immunotherapy, matrix metalloproteinase 
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Chapter 1 
Introduction 
Dementia 
 According to the Diagnostic and Statistical Manual of Mental Disorders, 
dementia is classified as a neurocognitive disorder that affects both cognitive 
function, such as memory, speech, language, judgment and reasoning, and the 
performance of everyday living activities, such as making a meal, paying bills or 
getting dressed. While young-onset cases of dementia are increasingly 
recognized, dementia is typically a disorder that affects the older population, age 
65 and up. In 2015, it was estimated that 46.8 million people worldwide were 
living with dementia (1). With the number of people aged over 60 expected to 
increase worldwide by 1.25 billion by 2050, accounting for 22% of the world’s 
population, it is crucial to understand the causes of dementia and develop 
treatments (2). 
 Alzheimer’s disease: First described by Alois Alzheimer in 1906, 
Alzheimer’s disease (AD) is the most common form of dementia, accounting for 
around 60% of all dementia cases (3). Clinically, AD is characterized by a 
worsening ability to remember new information, difficulty solving problems and 
completing familiar tasks at home, confusion with time or place, and trouble 
understanding visual images. Pathologically, AD is characterized by extracellular 
amyloid plaques made up of the amyloid-beta (Aβ) protein, neurofibrillary tangles 
that are comprised of intraneuronal inclusions of hyperphosphorylated tau, and 
neuronal loss (4). Aβ is produced when the larger amyloid precursor protein 
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(APP) is cleaved by both β and γ secretase. β secretase cleavage of APP occurs 
at amino acid 671 while γ secretase cleaves at either amino acid 711 or 713. This 
results in either Aβ1-40 or Aβ1-42. Aβ1-42 is the main Aβ species found in the 
amyloid plaques that characterize AD. Aβ1-40 associates mainly with the vessels 
in the brain, known as cerebral amyloid angiopathy (CAA); however, it can also 
be found in Aβ plaques. Cleavage of APP by α and γ secretase does not result in 
Aβ production since α secretase cleaves within the Aβ sequence of APP, 
resulting in a shorter and non-amyloidogenic fragment. Tau, the component of 
neurofibrillary tangles, modulates the stability of axonal microtubules and can be 
phosphorylated at several different sites in order to regulate its function. 
Hyperphosphorylation of tau, which occurs in AD, promotes aggregation of tau 
and eventual tangle formation and neuronal death.  
 Research into the cause of AD has revealed several genetic links and 
mutations associated with the disease. In 1993, apolipoprotein E (ApoE), a 
plasma protein that transports cholesterol in the brain, was identified as the most 
common significant genetic risk factor for AD (5-8). There are three alleles for the 
ApoE gene (ApoE 2, ApoE 3, and ApoE 4) and each person has two alleles. 
ApoE 3 accounts for about 70-80% of the ApoE gene pool, while ApoE 4 
accounts for 10-15% and ApoE 2 only accounts for 5-10% (9). ApoE 2, the least 
common allele, may be protective against AD compared to both ApoE 3 and 
ApoE 4. While ApoE 3 is the most common allele, it reduces the risk of 
developing AD compared to ApoE 4, suggesting a role for ApoE 4 in the 
pathogenesis of AD. Studies elucidating the mechanism of ApoE 4 in AD 
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revealed ApoE 4 had a decreased ability to clear Aβ compared to ApoE 3 and 
ApoE 2 (10, 11). ApoE 4 is also associated with an earlier age of onset. While 
having two ApoE 4 alleles further increases the risk of developing AD, it does not 
guarantee that the person will develop the disease. Some people with the ApoE 
4 allele never develop AD. Around the same time that ApoE 4 was identified as a 
genetic risk factor for AD, it was also discovered that certain mutations in either 
APP or in the core proteins of the γ secretase complex, known as presenilin 1 
(PS1) or PS2, cause early onset familial AD (12-16). Several mutations around 
the β and γ secretase cleavage sites and within the Aβ region on APP that 
increase Aβ production or aggregation have been identified in families with early 
onset AD where symptoms can appear as early as a person’s thirties. Missense 
mutations in PS1 and PS2 have also been identified in early onset cases and are 
the most common cause of familial AD. These rare, dominantly inherited 
mutations (seen in <5% of AD cases) either increase the rate of Aβ production or 
increase the cleavage of APP into the amyloidogenic Aβ1-42. Overall, both ApoE 4 
and the mutations in APP, PS1 and PS2 increase Aβ aggregation.   
 In 1992, it was hypothesized that Aβ aggregation was the initiating factor 
in AD progression since the genetic links to AD all lead to an increase in Aβ 
rather than tangles (17-19). This amyloid hypothesis states that an increase in Aβ 
aggregation either from decreased clearance or increased production, leads to 
microglial and astrocytic activation, altered neuronal ionic homeostasis, altered 
kinase and phosphatase activity which increases phosphorylation of tau leading 
to tangle formation, neurodegeneration and finally dementia. Other evidence 
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supporting this hypothesis comes from people with Down’s syndrome, 
frontotemporal dementia patients and several Aβ studies. Since APP is located 
on chromosome 21, people with Down’s with a complete triplication of 
chromosome 21 harbor three copies of the gene, which leads to early onset Aβ 
deposition. In fact, by age 40, virtually all adults with Down’s syndrome have 
sufficient levels of plaques and tangles for a pathological diagnosis of AD (20-
22). People with translocation who only have triplication of a portion of 
chromosome 21 without APP show a Down’s syndrome phenotype but do not 
develop AD (23). On the other hand, individuals who have the APP gene 
duplicated but not rest of chromosome 21 do not have Down’s syndrome but they 
do develop AD in their mid-50s (24). In frontotemporal dementia patients, 
mutations in the tau protein cause neurofibrillary tangle formation in the brain 
leading to dementia (25). However, the mutations that lead to neurofibrillary 
tangles do not induce Aβ aggregation and plaque formation, suggesting that 
neurofibrillary tangles are deposited after changes in Aβ metabolism occur (26). 
Finally, in cultured rat neurons, human Aβ1-42 oligomers induced tau 
hyperphosphorylation and injection of Aβ1-42 isolated from AD patients led to 
cognitive impairment in healthy rats (27, 28).  
 Due to the amyloid hypothesis, amyloid deposition and Aβ have become 
popular targets for AD therapeutics. One of the most promising potential 
therapeutics is anti-Aβ immunotherapy. In 1999, Schenk et al. reported that 
active immunization with Aβ1-42  prevented the development of Aβ plaques, 
neuritic dystrophy and astrogliosis in young PDAPP mice (6 weeks old) and 
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reduced the levels of Aβ in old PDAPP mice (11 months old) (29). Subsequently, 
it was shown that active immunization in APP/PS1 and TgCRND8 mice improved 
cognitive function and reduced Aβ deposition (30, 31). Active immunization in 
beagles and non-human primates also showed reduced Aβ deposition (32, 33).  
With the success of active immunization in animal models, a clinical trial in 
patients with AD using the full length Aβ peptide was initiated. While there were 
no adverse responses in the phase 1 study, a fraction of the patients in the 
phase 2a trial developed aseptic meningoencephalitis, which is an inflammatory 
reaction in the central nervous system (34, 35). The appearance of these 
adverse events halted the phase 2a trial and spurred the use of monoclonal 
antibodies to target Aβ and clear it from the brain. Initial studies showed that 
several different antibodies were able to reduce Aβ levels in mice (36, 37). In a 
series of studies, intracranial injection of an anti-Aβ antibody led to clearance of 
diffuse Aβ within 1 day and clearance of congophilic amyloid by 3 days (38, 39). 
Systemic administration of antibodies led to a significant decrease in congophilic 
plaques by 3 months; however, it was reported that passive immunotherapy 
caused microhemorrhages in mice (40). Further studies into the appearance of 
microhemorrhages showed a time dependent increase in the number of 
microhemorrhages and an increase in vascular amyloid deposition as well as 
association of the microhemorrhages with these vascular deposits (41-43).  
Again, due to the success of these antibodies in animal models, several 
clinical trials have been initiated. One of the most promising antibodies to enter 
clinical trials was bapineuzumab. In the phase 1 trial, patients received a single 
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administration of 0.5, 1.5 or 5 mg/kg of bapineuzumab and were tested 
cognitively before administration and again 16 weeks later (44). In this trial, 3 out 
of 10 patients in the highest dose group developed vasogenic edema, also 
termed an amyloid related imaging abnormality (ARIA-E). While the phase 1 trial 
wasn’t designed to measure effects on cognition, it was found that 
bapineuzumab improved mini mental state examination (MMSE) scores in the 
0.5 and 1.5 mg/kg groups. Bapineuzumab moved to a phase 2 clinical trial that 
included 234 patients, four doses (0.15, 0.5, 1 or 2 mg/kg) and six infusions of 
the drug 13 weeks apart (45). While there were no significant differences found in 
the primary efficacy analysis (MMSE scores only showed a trend, no change in 
cerebrospinal fluid (CSF) biomarkers, or brain or ventricular volume), 9.7% of the 
bapineuzumab treated patients developed reversible vasogenic edema. The MRI 
detected edema (ARIA-E) was more common in the higher dose groups and in 
patients with the ApoE 4 allele. In a phase 3 clinical trial of bapineuzumab 
treatment in ApoE 4 carriers, there were, again, no improvements in clinical 
outcomes and 14.2% of the highest dose group (2 mg/kg) developed ARIA-E 
(46).  
 There are several proposed mechanisms for how anti-Aβ antibodies clear 
Aβ from the brain. The first involves the traditional role of an antibody to opsonize 
antigens leading to complement activation and phagocytosis (36). For this 
mechanism, anti-Aβ antibodies bind to Aβ and then the Fc portion of the antibody 
binds to the Fcγ receptor (FcγR) on microglia leading to phagocytosis. While this 
mechanism assumes that the antibody crosses the blood brain barrier (BBB), the 
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“peripheral sink” mechanism does not make this assumption (37). In this 
proposed mechanism, antibodies clear Aβ from the blood, creating an 
Aβ concentration gradient between the brain and the blood. This causes Aβ to 
then be transported down its concentration gradient from the brain to the blood. 
Finally, the last proposed mechanism is that the antibody modifies the secondary 
structure of the Aβ monomers so that they are less likely to aggregate into 
oligomeric or fibrillar forms (47). It is important to note, however, that these three 
mechanisms are not mutually exclusive. The antibodies can utilize these 
mechanisms to different degrees and may depend on the specific binding sites of 
each antibody and the isotype (48, 49). For example, antibodies that do not bind 
the fibrillar forms of Aβ may not have the ability to activate microglia via the FcγR, 
but could utilize the peripheral sink method instead.  
 Vascular cognitive impairment and dementia: Inadequate blood flow to 
any part of the body can cause damage to cells and since the brain requires a 
large blood supply and has the most intricate system of blood delivery, it is 
especially susceptible to damage by changes in blood flow. Changes in blood 
flow that damage areas of the brain causing cognitive decline is known as 
vascular cognitive impairment and dementia (VCID) and is the second leading 
cause of dementia. It is estimated that VCID accounts for 10-40% of dementia 
cases (50); however, issues with diagnostic criteria and the recent inclusion of 
cognitive disorders ranging from mild cognitive impairment all the way to 
dementia make estimating the prevalence of VCID difficult. While recent 
advances in neuroimaging have made the diagnosis of VCID easier, defining the 
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pathology underlying the cognitive decline in VCID is still difficult. For instance, 
infarcts can vary in size as well as location, can occur in patients with and without 
dementia, and can also be found in patients with AD. Further studies are required 
to understand the cognitive consequences of cerebrovascular pathologies. 
Cerebral small vessel disease (SVD) is a leading cause of cognitive 
decline in the elderly and the most common form of VCID. SVD is defined as the 
pathological processes that affect the small vessels of the brain (small arteries, 
arterioles, capillaries and small veins). The main consequences of SVD include 
lacunar infarcts, white matter lesions and microhemorrhages. Hypertension, 
arteriolosclerosis, cerebral autosomal dominant arteriopathy with subcortical 
ischemic strokes and leukoencephalopathy (CADASIL) and CAA are the most 
common causes of SVD.    
 Cerebral amyloid angiopathy is a common pathology found in 80-100% of 
AD cases, but it can also be found in patients without other AD pathologies (51). 
This is termed sporadic or spontaneous CAA and appears in 10-30% of the 
elderly population (51). Advanced CAA can induce loss of smooth muscle cells, 
microaneurysms and microhemorrhages (52). While CAA is most commonly 
seen as the cause of spontaneous intracerebral hemorrhage, there is increasing 
evidence that it is a contributor to cognitive decline and, therefore, VCID. Over 
40% of CAA patients who have intracerebral hemorrhages also have some 
degree of cognitive decline (53). Intracerebral hemorrhages, cerebral 
microbleeds, white matter hyperintensities and cerebral infarcts could be 
contributing mechanisms to the cognitive decline seen in CAA patients.  
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 While VCID encompasses a wide range of pathologies, there are also 
several risk factors for VCID. Some risk factors include hypertension, 
hypercholesterolemia, diabetes and hyperhomocysteinemia; however, the most 
common risk factor for VCID is a stroke. Depending upon location and volume of 
the stroke, degree of related neuronal damage, and the presence of pre-existing 
cognitive impairment and vascular pathology, cognitive decline after a stroke can 
occur. In fact, as the risk of death from strokes has declined due to lesser stroke 
severity and improved management, the number of stroke survivors with 
cognitive decline has increased. The risk of post-stroke dementia has been 
estimated to be around 10% after the first stroke, depending on location and size, 
while cognitive decline after a recurrent stroke rose to 30% (54, 55). Other 
studies estimate that dementia occurs in about 30% of patients with a history of 
stroke (56). The risk of post-stroke dementia is more likely when vascular co-
morbid conditions are present, such as hypertension, atrial fibrillation or diabetes 
(57, 58). Modification of risk factors for stroke could, therefore, reduce the risk of 
stroke and post-stroke dementia. 
 Co-morbidity of AD and VCID: There is increasing awareness of AD with 
cerebrovascular pathologies and it is estimated that about 40-50% of AD patients 
have co-morbid vascular injury (59-61). Vascular co-morbidities are also more 
commonly found in late stage AD and in the oldest old (62). It is also thought that 
vascular injuries co-morbid with AD act as an extra “hit” to the brain that lowers 
the threshold for cognitive impairment in persons with AD pathology (63). It is 
suggested that patients with both AD and VCID have a shorter time to dementia 
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and their rate of cognitive decline is faster (64). Other studies have shown that 
VCID and AD are additive when it comes to cognitive deficits (65-68). While the 
role that vascular injury plays in the progression of AD remains unknown, it has 
been hypothesized that vascular dysfunction leads to Aβ accumulation in the 
parenchyma and blood vessels (69, 70). This high prevalence of co-morbidity 
patients and the possibility that vascular injury impacts cognition could affect 
treatments for dementia.   
 
Neuroinflammation 
 It has long been thought that the brain was immunologically privileged with 
no resident or infiltrating immune cells; however, it is now understood that the 
cells of the brain are capable of a wide range of neuroinflammatory responses. 
The glial cells of the brain (astrocytes, microglia, oligodendrocytes, and 
pericytes) are all capable of an inflammatory response, but the main regulator of 
inflammation in the brain is the microglia cell (71). Originally thought to be 
derived from the macrophage cell line, it is now understood that yolk-sac derived 
fetal macrophages are the precursors for microglia (72, 73). Depending on the 
stimuli, macrophages are capable of a variety of inflammatory responses. The 
presence of tumor necrosis factor alpha (TNFα) or interferon gamma (IFNγ) 
stimulates macrophages to release several pro-inflammatory cytokines and to 
produce reactive oxygen species (74-76). This state, termed M1 or pro-
inflammatory, has high microbicidal activity and is an important defense 
mechanism for the body. However, if this state goes unchecked, it can cause 
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damage to the tissues and it has been implicated in the development of 
autoimmune disorders (77). On the other end of the spectrum is the M2a or 
wound healing and repair state. Activated by interleukin-4 (IL-4) or IL-13, this 
state is generally seen in allergic responses and plays a role in extracellular 
matrix remodeling and deposition (78, 79). Immune complexes (IgG antibody-
antigen complexes), toll-like receptor activation, or IL-1 receptor ligands can all 
stimulate an M2b or immune complex mediated state (78, 79). This state is a 
combination of a pro-inflammatory and wound healing and repair state. Finally, 
the M2c, or acquired deactivation state, is activated by IL-10 and contributes to 
an environment that is defective in pathogen killing and enhances survival of 
organisms (78, 79). These states have been used to describe peripheral 
macrophage inflammatory phenotypes, but it has been shown that microglia are 
capable of expressing many of these macrophage markers (80). Table 1.1 shows 
the specific markers used to categorize the inflammatory phenotypes in the brain.  
 Alzheimer’s disease: When Alois Alzheimer first described the 
pathologies of AD, he also noticed inflammation of the glia. For decades, it was 
believed that neuroinflammation had a negative influence on the disease 
progression of AD. Initially, neuroinflammation in AD focused on the “autotoxic 
loop” which was first described by E.G. McGeer and P.L. McGeer in 1998 (81). In 
this “vicious cycle,” cellular debris caused by AD pathologies activates microglia, 
this activation of microglia leads to the release of cytotoxic cytokines that causes 
a more rapid neuronal death which then provides more cellular debris to start the 
cycle over again. Evidence to support this cycle is the increased IL-1β and TNFα 
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levels found in the brains and CSF of AD patients; however, these levels are not 
high enough to cause significant neuronal death (81). Attempts to recreate this 
“autotoxic loop” often led to clearance of Aβ plaques in transgenic mice, showing 
that neuroinflammation could be a beneficial process in AD.  
To determine the effects of neuroinflammation on AD pathologies, several 
studies have induced the different neuroinflammatory phenotypes in AD 
transgenic mice. Lipopolysaccharide (LPS) is a gram-negative bacterial cell 
surface proteoglycan that stimulates a pro-inflammatory response in wildtype 
mice that peaks around 3 days (82). When injected into APP/PS1 mice, LPS 
stimulated Aβ clearance between 0 and 3 days (83). However, when LPS was 
injected into tau transgenic mice, tau pathology was exacerbated 7 days after the 
injection (84). Another study using the 3XTg mouse model that has both Aβ 
deposition and tau pathology showed that LPS injection exacerbated tau 
hyperphosphorylation (85). This suggests that Aβ and tau have different 
responses to the inflammatory phenotypes and caution should be used when 
applying findings in Aβ depositing mice to the overall condition of AD.  
 Genetic manipulation of individual inflammatory cytokines has yielded 
similar results to LPS induced neuroinflammation. Overexpression of TGFβ, a 
marker for the acquired deactivation phenotype, reduced Aβ deposition and 
increased microglial activation in APP mice; however, in this study, while 
parenchymal amyloid was reduced, there was a significant increase in CAA (86). 
Blockage of the pro-inflammatory cytokine TNFα in 3XTg mice resulted in 
increased Aβ and tau pathology (87). Overexpression of IL-1β, another pro-
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inflammatory cytokine, in APP/PS1 mice resulted in decreased Aβ deposition and 
increased microglial activation (88). 
As mentioned previously, one of the mechanisms of anti-Aβ 
immunotherapy involves activation of the immune system in the brain. When 
injected either directly into the parenchyma or systemically, anti-Aβ antibodies 
initiate a switch from an anti-inflammatory phenotype in Aβ depositing mice to a 
pro-inflammatory phenotype by increasing expression of IL-1β, TNFα, and IL-6 
(89). This switch in phenotype occurs before any reduction in Aβ is seen, 
suggesting that activation of microglia to produce a pro-inflammatory phenotype 
is a mechanism for Aβ clearance. However, it should be noted that IL-1β has 
been shown to be neurodegenerative and can cause tau hyperphosphorylation 
(90, 91).  
 While there is evidence that a pro-inflammatory phenotype can reduce Aβ, 
the effect of an anti-inflammatory or wound healing and repair phenotype is less 
clear. As Aβ depositing mice age and Aβ deposition increases, the inflammatory 
phenotype becomes increasingly polarized to a wound healing and repair 
phenotype. Lithium, which decreases pro-inflammatory cytokines and increases 
wound healing and repair cytokines, is also an inhibitor of glycogen-synthase 
kinase 3 β, which is known to phosphorylate tau (92, 93). When 
APPSwDI/NOS2-/- mice were treated with lithium, the wound healing and repair 
phenotype was enhanced and Aβ deposition was increased (94). This suggests 
that the wound healing and repair phenotype increases Aβ deposition. Further 
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studies are required in order to fully understand the effect of the wound healing 
and repair phenotype on AD pathologies. 
 Little is also known about the neuroinflammatory phenotype in the human 
AD brain. Our research group analyzed the frontal cortex of early, mid and late 
stage AD patients for several neuroinflammatory markers and found that early 
stage patients were either polarized to a pro-inflammatory or a wound healing 
and repair phenotype (95). Further analysis of the pathology of early stage AD 
brains showed that the patients who were polarized to a wound healing and 
repair phenotype had more CAA and these patients had significantly more 
cerebrovascular risk factors present. Late stage AD brains were not polarized 
towards any phenotype but instead had a mix of markers from all the 
phenotypes. This heterogeneity in neuroinflammation in early stage AD brains 
could influence responses to therapies.  
 Vascular cognitive impairment and dementia: Even less is known 
about neuroinflammation’s role in VCID compared to its role in AD. It is 
hypothesized that neuroinflammation and oxidative stress play a key role in 
neurovascular dysfunction. Some patients with spontaneous CAA present with 
CAA related inflammation as well as white matter abnormalities (52). 
Hypertensive patients show deficits in autoregulation of cerebral perfusion in 
response to blood pressure changes and this leads to aberrant angiotensin II 
signaling. Angiotensin II, which mediates vascular remodeling in response to 
blood pressure dysregulation, has been linked to the stimulation of NADPH 
oxidase (96, 97). NADPH oxidase, which is also increased in hypoperfusion 
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models, is an important source of vascular oxidative stress and reactive oxygen 
species (98). This increase in reactive oxygen species can stimulate 
inflammatory pathways via toll-like receptors and lead to BBB breakdown. This 
vascular damage via inflammation most likely interferes with neurovascular 
coupling and the proliferation, migration and differentiation of oligodendrocytes 
contributing to white matter damage and VCID (99). Further studies are required 
to elucidate the connection between inflammation and VCID.   
 
Matrix Metalloproteinases  
 Matrix metalloproteinases (MMPs) are a family of proteases that regulate 
many physiological processes including activation of growth factors, cleavage of 
zymogens and remodeling of the extracellular matrix (100). Due to their large 
variety of substrates, the majority of MMPs have been linked to the development 
of several diseases such as cancer metastasis, chronic inflammation, abdominal 
aortic aneurysms and several neurological disorders (101-104). Recently, the 
remodeling of the extracellular matrix and disruption of the neurovascular unit via 
MMPs have been implicated in vascular cognitive impairment. Consisting of 
astrocytic end feet, neurons, pericytes and endothelial cells, the neurovascular 
unit plays a key role in maintaining homeostasis in the brain and formation of the 
BBB. MMPs have been shown to break down the extracellular matrix and the 
tight junctions that form the BBB, leading to leakage and hemorrhaging into brain 
tissue (105).  
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MMPs are a family of 23 proteases in humans (24 in mice) that degrade 
the extracellular matrix along with other substrates such as contractile proteins, 
tight junction proteins, and pro-forms of signaling molecules (100). Based on 
substrate specificity, MMPs are separated into five classes: collagenases, 
stromelysins, a heterogeneous group, membrane anchored MMPs, and finally, 
the gelatinases. The gelatinase class, which is present in the brain, includes 
MMP2, which is also known as Gelatinase A, and MMP9, also known as 
Gelatinase B. The gelatinase class of MMPs can degrade gelatin, cytokines 
(100) and even Aβ (106, 107), but they also have roles in axonal growth, synaptic 
plasticity and vascularization (108-112). Due to their variety of substrates, it is 
important to maintain control over MMP2 and MMP9 activity; therefore, they are 
endogenously regulated at several different levels. Similar to other MMPs, gene 
expression of MMP2 and MMP9 is regulated by cytokines, growth factors and 
other proteins. The pro-inflammatory cytokines TNFα and IL1β can stimulate 
transcription of MMP9 (113, 114), while activator protein 2, specificity protein 1, 
and polyomavirus enhancer-A binding protein 3 can stimulate transcription of 
MMP2 (115). At the protein level, MMP2 is constitutively expressed in the brain 
while MMP9 expression is induced by neuroinflammation. However, both are 
secreted as zymogens that require cleavage via other MMPs. For MMP2 
activation, a complex of MMP14, which is also known as membrane type 1 MMP 
(MT1-MMP), tissue inhibitor of metalloproteinase 2 (TIMP2) and proMMP2 must 
be formed. MMP14 is one of six enzymes that include a C terminal hydrophobic 
transmembrane domain that anchors the enzyme to the plasma membrane and 
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thus restricts its activity to the cell surface (116, 117); this then constrains the 
action of MMP2 as well (118). Activation of proMMP9 requires cleavage via 
MMP3 which can also be activated via neuroinflammation (100). Finally, the 
endogenous inhibitor TIMP1 binds and inhibits MMP9 (100). Active MMP2 can 
be inhibited by TIMP2, even though TIMP2 is necessary, along with MMP14, for 
activation of proMMP2 (100). Therefore, TIMP2 participates in activation of 
proMMP2 and inhibition of active MMP2. Recent studies have also shown that 
nitric oxide can regulate MMP9 activity and the activity of TIMP1 (119). The 
MMP2 and MMP9 systems, which are summarized in Figure 1.1, are associated 
with tight junction breakdown leading to BBB leakage (120).  
Alzheimer’s disease: Of patients with AD, almost 95% have CAA (121). 
The main criterion for clinical diagnosis of CAA is the presence of cortical 
cerebral brain hemorrhage which causes and/or contributes to 
neurodegeneration and dementia (122). Patients with AD and multiple 
microhemorrhages had more severe cognitive impairment compared to AD 
patients without microhemorrhages (123). MMP2 and MMP9 have been widely 
associated with BBB disruption and microhemorrhages in CAA and AD. 
In postmortem AD brains, MMP9 was elevated in neurons, senile plaques, 
tangles and within the vascular wall (124). MMP9 was also elevated in the 
plasma, hippocampus and cerebral cortex of AD patients (124-127). Bruno et al 
demonstrated an increase in MMP9 activity during the progression of AD that 
correlates with cognitive impairment (128). MMP2 was found in reactive 
astrocytes around Aβ plaques and near cerebral microvascular fibrillar amyloid 
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deposits in Tg-SwDI mice (129). MMP9 expression was also shown in CAA 
vessels in APP transgenic mice (130). This suggests that MMP2 and MMP9 play 
a role in BBB breakdown and hemorrhaging in CAA.  
 It has long been known that AD induces a neuroinflammatory response, 
although the effect of this inflammation remains unknown. During AD, peripheral 
immune cells, such as lymphocytes, monocytes and neutrophils, can cross the 
BBB and infiltrate the brain (131). Aβ25-35, a truncated form of the Aβ peptide, has 
been shown to activate invading neutrophils, the most abundant immune cell to 
infiltrate the brain, and stimulate the release of proMMP9 (132). While this 
stimulation and release does not activate proMMP9, there are several other 
proteases, such as MMP3, that can cleave and activate the released proMMP9. 
This activation of neutrophils and release of proMMP9 indicates that MMP9 may 
play a role in the inflammatory response during AD.  
 Tau has also been shown to be a substrate for MMP3 and MMP9 (133). 
While MMP3 cleavage of tau does not result in tau aggregation, MMP9 cleavage 
does result in tau oligomer formation. Frost et al. previously demonstrated that 
extracellular pro-aggregatory tau can be incorporated into neurons and induce 
neurotoxic intracellular tau aggregation which spreads to other cells (134). This 
suggests that cleavage of tau by MMP9 could contribute to neurofibrillary tangle 
formation. 
Vascular cognitive impairment and dementia: The gelatinases have 
also been shown to play a role in VCID, particularly during hemorrhagic 
transformation after stroke and intracerebral hemorrhage.  
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After a stroke occurs, the BBB around the ischemic area is weakened and 
bleeding into the brain can occur. Termed hemorrhagic transformation, this 
opening of the BBB occurs in 10% to 40% of patients with ischemic stroke (135, 
136) and greatly increases the morbidity and mortality after stroke (137, 138). 
The only FDA approved therapy for stroke, tissue plasminogen activator (tPA), 
increases the occurrence of hemorrhagic transformation 10-fold when 
administered outside the narrow 3-hour window when it is effective (139, 140). 
While tPA works to restore blood flow to the ischemic area by breaking down 
fibrin based clots, it can activate and release MMP2, MMP9 and MMP3 (139, 
141-143).  
 Hemorrhagic transformation after ischemic stroke can be separated into 
two phases: early phase (up to 18-24 hours after stroke onset) and late phase 
(24 hours after stroke onset) (144). During the early phase, leukocytes infiltrate 
the brain and are considered to be the main source of MMP9. Ischemic stroke 
quickly initiates an immune response causing leukocytes to bind to endothelial 
cells in the vasculature (145). In humans, MMP9 mRNA levels in peripheral 
leukocytes are increased as soon as 3-5 hours after stroke and activity of MMP9 
peaks at 6-8 hours after stroke (145-147). Plasma levels of MMP9 have been 
shown to be predictive of hemorrhagic transformation and correlate with BBB 
injury (148-151). MMP9 and MMP2 are increased in plasma 3-8 hours after 
stroke in rats and mice as well (152, 153). The brain is also an important source 
of MMP2 in the early phase of hemorrhagic transformation. Primarily derived 
from astrocytes and endothelial cells, MMP2 is increased in the post-stroke brain 
 20 
within 1-3 hours in rats and mice and remains elevated for several days (154-
156). MMP14 is also increased after stroke, which could subsequently increase 
MMP2 activity (157, 158). This rise in MMP2 correlates with degradation of 
claudin-5 and occludin, two crucial tight junction proteins, leading to BBB 
breakdown in rodent models of stroke (105, 155, 159, 160).  
In the late phase of hemorrhagic transformation, brain cells are the major 
source of MMPs. MMP9 can be expressed in astrocytes, neurons, microglia and 
endothelial cells and MMP9 is localized to these immunoreactive cells during the 
late phase of hemorrhagic transformation (112, 161). MMP3 was shown to be 
increased within 24 hours after stroke onset (162) and MMP3 knockout mice 
have a reduced rate of hemorrhagic transformation in a middle cerebral artery 
occlusion model with tPA treatment (163). This increase in MMP3 can increase 
the activity of MMP9 via cleavage of proMMP9, contributing to hemorrhagic 
transformation. 
 While the role of MMPs in hemorrhagic transformation after ischemic 
stroke has been studied in depth, their role in hemorrhagic stroke is less clear. 
Human studies have revealed elevated levels of MMP9 in peripheral blood after 
intracranial hemorrhage and were associated with worse neurological outcomes 
(164). Another study showed that while MMP2 levels remained stable after 
hemorrhagic stroke, MMP9 levels were increased and could possibly have 
contributed to cerebral edema after stroke (165). However, MMP9 is more 
commonly associated with CAA associated hemorrhage. 
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Mouse models 
 Alzheimer’s disease: Over the last 20 years, many mouse models of Aβ 
deposition have been created using the early onset familial mutations found in 
humans. One of the earliest mouse models was the PDAPP mouse first 
described by Dora Games in 1995 (166). The PDAPP mouse has a platelet 
derived growth factor-driven human APP gene with the Indiana mutation 
(V717F), which increases the Aβ1-42/Aβ1-40 ratio in humans. This mouse model 
shows cognitive decline around 4 months, plaque deposition and gliosis around 6 
months and synaptic loss at 9 months. Another model using an APP mutation 
(Swedish mutation, KM670/671NL) is the Tg2576 mouse developed by Karen 
Hsiao in 1996 (167). This model shows synaptic loss at 4.5 months, cognitive 
decline around 6 months, gliosis at 10 months, and plaque deposition around 11 
months. Mutations in PS1 have also been shown to cause early onset familial AD 
and have also been used to create mouse models of AD. In 1996, Karen Duff 
developed PS1 mouse models that increase the amount of Aβ1-42 (168). One 
downside to single transgenic mice, like the Tg2576 mouse, is that they develop 
fewer plaques and plaque deposition occurs at a later age. To accelerate plaque 
deposition and to increase the plaque load, the double transgenic PS/APP 
mouse was developed in 1998 (169). Created by crossing the Tg2576 mouse 
and another mouse with a mutant PS1 gene (M146L), the PS/APP mouse shows 
plaque deposition starting at 6 months that increases with age, astrogliosis at 6 
months, microglial activation at 12 months, and cognitive deficits around 15 
months. Using this idea of double transgenic mouse models, Jankowsky 
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developed the APPSwe/PSEN1dE9 (APP/PS1) mouse (170, 171). The APP/PS1 
mouse begins developing plaques around 6 months of age and has abundant 
levels by 9 months with no tangle formation. Astrogliosis also begins with plaque 
deposition at 6 months and increases with age (172). CAA has also been shown 
to appear as early as 6 months and increase with age, although progression was 
slower than the Tg2576 mouse, perhaps due to the higher Aβ1-42/Aβ1-40 ratio 
(173). Behavioral changes in these mice have been well characterized and show 
contextual memory deficits in fear conditioning tests starting at 6 months (174, 
175). At 7 months, spatial learning is comparable to wildtype mice but is impaired 
by 12 months when tested on the Morris water maze (176, 177). While these 
models only represent one of the three characteristic pathologies of AD, they are 
sufficient for studying treatments that target Aβ deposition.  
 Vascular cognitive impairment and dementia: With many different 
causes of VCID, there have been several mouse models developed to study the 
disease. The bilateral common carotid artery stenosis model places micro-coils 
around the common carotid arteries to reduce blood flow to the brain and induces 
cognitive impairments and neuroinflammation (178). Both spontaneously 
hypertensive rats and cerebral autosomal dominant arteriopathy with subcortical 
infarcts and leukoencephalopathy (CADASIL) mice model cerebral small vessel 
disease, a common form of VCID. Spontaneously hypertensive rats develop high 
blood pressure with age and eventually develop ischemic lesions and memory 
impairments (179). The CADASIL mouse model, R90C, has white matter 
degeneration, age-associated vascular smooth muscle cell loss, and subcortical 
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infarcts (180, 181). Another set of mouse models that induce VCID involves the 
elevation of plasma homocysteine levels.  
 Homocysteine is a non-protein forming amino acid involved in the 
metabolism of cysteine and methionine (182). During normal metabolism, ATP 
activates methionine to form S-adenosylmethionine (SAM). SAM is a methyl 
donor to several different receptors and forms S-adenosylhomocysteine (SAH) 
as a by-product of this methyl reaction. SAH can then be hydrolyzed to form 
homocysteine. Homocysteine can also go through a re-methylation process to 
form methionine again. In this process, folate is reduced to tetrahydrofolate which 
is then converted to 5, 10-methylenetetrahydrofolate. Methylenetetrahydrofolate 
reductase (MTHFR) reduces 5, 10-methylenetetrahydrofate to 5-
methyltetrahydrofolate. Finally, 5-methyltetrahydrofolate and vitamin B12 add a 
methyl group to homocysteine to form methionine again. Homocysteine can also 
go through a transsulfuration pathway to form cysteine. Serine can be 
enzymatically added to homocysteine by cystathionine β synthase (CBS) and 
vitamin B6 to form cystathionine (183). Cystathionine can then be cleaved by 
cystathionine gamma-lyase (CGL) to form cysteine. While cysteine can be 
converted back to cystathionine, cystathionine cannot be converted to 
homocysteine again. These homocysteine metabolic pathways are shown in 
Figure 1.2.  
 Elevated plasma homocysteine levels, termed hyperhomocysteinemia 
(HHcy), has been identified as a risk factor for cardiovascular disease, stroke, 
VCID, and AD (184-187). Normal levels of homocysteine range between 5-15 
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µmol/L. Levels between 15-30 µmol/L are considered mild, levels at 30-
100 µmol/L are moderate and levels above 100 µmol/L are considered severe 
HHcy. In the periphery, homocysteine increases the formation of reactive oxygen 
species, which alters smooth muscle function and promotes proliferation of 
smooth muscles cells (188). Homocysteine also increases platelet aggregation 
which can contribute to brain infarcts (188). Serum homocysteine levels are 
inversely related to cognitive function in patients with dementia and elevated 
levels are more common among VCID patients than among AD patients (189, 
190). While studies have shown an association between homocysteine levels 
and hippocampal atrophy, white matter lesions, and lacunar infarcts, the 
mechanism of HHcy-induced damage remains unknown (191, 192). It is unclear 
whether the increased risk of VCID is due to a direct effect of homocysteine or 
the lack of B vitamins which can cause HHcy.  
 To clarify this lack of clarity, several animal models have shown that high 
plasma levels of homocysteine are sufficient to cause cognitive deficits and 
vascular adverse events in the brain with and without B vitamin deficiency. 
Induction of HHcy in an animal model can be achieved via genetic manipulation 
or diet. Genetic manipulation of either CBS, which converts homocysteine to 
cystathionine, or MTHFR, which is the rate-limiting step in homocysteine 
conversion to methionine, can produce mouse models of HHcy. In humans, 
deficiencies in CBS result in elevated plasma levels of homocysteine and 
thrombosis, and are the most common cause of hereditary HHcy. CBS+/- 
heterozygote mice have a 50% lower CBS activity compared to wildtype mice 
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and develop mild HHcy (193). These mice show substantially decreased dilatory 
responses compared to controls (194) and it has also been shown that cerebral 
arteriolar walls are 25% thicker in CBS+/- heterozygote mice (195). In humans, 
there are several polymorphisms in MTHFR that produce HHcy and neurological 
conditions such as a progressive demyelinating neuropathy and cognitive 
impairment (196-198). Chen et al. deleted the MTHFR gene to create a mouse 
model of HHcy that exhibits motor and gait abnormalities within 5 weeks after 
birth (199). MTHFR-/- homozygotes also present with abnormal lipid deposition in 
the aorta and disruption of the laminar structure of the cerebellum with no 
obvious changes in the cortex or cerebrum.  
Unlike MTHFR and CBS knockout mice, dietary induction of HHcy allows 
for age related HHcy to be studied. Dietary induction of HHcy in mice and rats 
can be achieved through a reduction in vitamins B6, B9 and B12, enrichment in 
methionine, or elevated levels of homocysteine. A combination of these diets can 
also be used to induce HHcy. Vitamins B6, B9 and B12 act as essential cofactors 
for the conversion of homocysteine to methionine or cysteine and enrichment in 
methionine causes an increase in conversion to homocysteine. In 2008, Treon et 
al. showed that feeding mice a B vitamin deficient diet resulted in cognitive 
impairment on the Morris water maze and decreased density of brain capillaries 
(200). Kim et al. fed 6-month-old Sprague-Dawley rats a folate deficient diet for 8 
weeks and saw an increase in homocysteine levels, ultrastructural changes to 
cerebral capillaries, endothelial damage, swelling of pericytes, basement 
membrane thickening, and fibrosis (201). Rats fed a diet high in homocysteine for 
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5 or 15 months both showed cognitive impairments, decreased acetylcholine in 
the brain, and cortical microhemorrhages (202).  
To develop a model of VCID, our research group took 3-month-old 
C57BL6 wildtype (WT) mice and placed them on a combination diet that was 
deficient in vitamins B6, B9 and B12 and enriched in methionine for 3 months 
(203). At the end of the 3 months, plasma homocysteine levels reached 
moderate levels in the mice on the homocysteine diet (82.93 ± 3.561 µmol/L 
compared to 5.89 ± 0.385 µmol/L in the control mice). When tested on the 
radial arm water maze, which tests spatial memory and requires hippocampal 
and cortical brain regions, these mice exhibited significant cognitive impairments 
(Figure 1.3A). Microhemorrhages were the main cerebrovascular pathology 
induced by the HHcy diet as shown by Prussian blue staining and MRI (Figure 
1.3B). Neuroinflammation has been hypothesized to be a key mediator in VCID. 
In the HHcy mouse model, several pro-inflammatory cytokines were significantly 
increased compared to control mice while anti-inflammatory markers were not 
(Figure 1.3C). As mentioned earlier, MMP2 and MMP9 have been shown to 
degrade tight junctions and MMP9 can be activated by pro-inflammatory 
cytokines. qPCR showed a significant increase in MMP14, MMP2, MMP3 and 
MMP9 gene expression (Figure 1.3D) and gel zymography showed a significant 
increase in MMP2 and MMP9 activity (data not shown).  
Co-morbidity of AD and VCID: Using this mouse model of VCID via 
induction of HHcy, our research group then developed a co-morbidity mouse 
model to determine the effects of VCID on Aβ pathology (204). Six-month-old 
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APP/PS1 and wildtype mice were placed on either the control or HHcy diet for six 
months. Plasma homocysteine levels reached moderate levels again in both the 
APP/PS1 and wildtype mice and were significantly increased compared to 
controls (WT control: 6.85 ± 0.8 µmol/L, WT HHcy: 68.23 ± 12.1 µmol/L, 
APP/PS1 control: 7.65 ± 1.4 µmol/L, APP/PS1 HHcy: 64.21 ± 8.3 µmol/L). 
Using the two-day radial arm water maze to test cognitive changes, the APP/PS1 
mice on the HHcy diet showed additive cognitive deficits (Figure 1.4A), 
suggesting an additive effect of the cerebrovascular pathology and Aβ 
deposition. The co-morbidity mice also showed a switch from an anti-
inflammatory phenotype (M2a) to a pro-inflammatory phenotype (M1) (Figure 
1.4B). Total levels of Aβ were not affected; however, there was a redistribution of 
amyloid. Congo red staining showed a decrease in parenchymal compact 
plaques and an increase in CAA in the APP/PS1 mice on the HHcy diet (Figure 
1.4C). Analysis of microhemorrhages showed a significant increase in the 
APP/PS1 mice on the HHcy diet (Figure 1.4D) and gene expression analysis 
showed a significant increase in MMP14, MMP3 and MMP9 (Figure 1.4E). 
Overall, with the additive cognitive deficits and cerebrovascular pathology, this 
mouse model of HHcy in APP/PS1 mice can be used for studies of co-morbid 
dementia.   
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Figure 1.1 Summary of the MMP2 and MMP9 systems. Furin and plasmin 
increase MMP14 levels, which in turn forms a complex with proMMP2 and TIMP2 
to activate MMP2. TIMP2 also inhibits MMP2 activity. Pro-inflammatory cytokines 
increase proMMP3 and proMMP9. MMP9 is activated by MMP3 and inhibited by 
TIMP1. Both MMP2 and MMP9 break down the blood brain barrier.   
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Figure 1.2 Biochemical pathways linking homocysteine and B vitamins. 
Methionine is converted to homocysteine by methylation and subsequent 
hydrolysis. Homocysteine can be cycled back to methionine via the folate cycle, 
which is catalyzed by MTHFR and the essential cofactor vitamin B12. 
Alternatively, homocysteine can be further metabolized to cysteine via CBS and 
the essential cofactor vitamin B6. Homocysteine conversion to cysteine occurs 
primarily in the liver. All other reactions are ubiquitous.  
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Figure 1.3 HHcy in wildtype mice models VCID. A) Two-day radial arm water 
maze data. Data are given as block numbers where each block is the average of 
3 trials. * indicates P<0.05 and ** indicates P<0.01 by individual block t-test. B) 
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Prussian blue and MRI detected microhemorrhages. ** indicates P<0.01 by t-test. 
C) qPCR analysis for pro-inflammatory and anti-inflammatory markers (D) and 
MMP2 and MMP9 system markers. Data are shown as fold change from control. 
* indicates P<0.05 and ** indicates P<0.01 by t-test.   
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Figure 1.4 HHcy in APP/PS1 mice models co-morbid dementia. A) Two-day 
radial arm water maze data. Data are given as block numbers where each block 
is the average of 3 trials. ** indicates P<0.01 by individual block t-test. B) qPCR 
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analysis for pro-inflammatory and anti-inflammatory markers. Data are shown as 
fold change from control. C) Quantification of the percent area occupied by 
positive Congo red staining in the frontal cortex and hippocampus of APP/PS1 
mice. ** indicates P<0.01 compared to APP/PS1 mice on control diet. D) 
Prussian blue detected microhemorrhages. ** indicates P<0.01 compared to the 
control group for the given genotype. E) qPCR analysis for MMP2 and MMP9 
system markers. Data are shown as fold change from control. ** indicates P<0.01 
compared to controls for each genotype. 
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Table 1.1 Specific markers for each inflammatory phenotype. 
Pro-inflammatory 
(M1) 
Wound healing and 
repair (M2a) 
Immune complex 
mediated (M2b) 
Acquired 
deactivation (M2c) 
IL-1β IL-10 CD86 TGF1β 
TNFα ARG1 FcγR1 SPHK1 
IL-6 YM1 FcγR3 MRC1 
IL-12a Fizz IL-10 IL-10 
IL-12b IL-1Ra Low IL-12 Low IL-12 
Marco MRC1   
Low IL-10 Low IL-12   
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Abstract 
The polarization to different neuroinflammatory phenotypes has been described 
in early Alzheimer’s disease, yet the impact of these phenotypes on Aβ pathology 
remains unknown. Short term studies show that induction of an M1 
neuroinflammatory phenotype reduces Aβ, but long term studies have not been 
performed that track the neuroinflammatory phenotype. Wildtype and APP/PS1 
transgenic mice aged 3-4 months received a bilateral intracranial injection of 
adeno-associated viral (AAV) vectors expressing IFNγ or GFP in the frontal 
cortex and hippocampus. Mice were sacrificed 4 or 6 months post-injection. 
ELISA measurements were used for IFNγ protein levels and biochemical levels of 
Aβ. The neuroinflammatory phenotype was determined through qPCR. Microglia, 
astrocytes, and Aβ levels were assessed with immunohistochemistry. AAV 
expressing IFNγ induced an M1 neuroinflammatory phenotype at 4 months and a 
mixed phenotype along with an increase in Aβ at 6 months. Microglial staining 
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was increased at 6 months and astrocyte staining was decreased at 4 and 6 
months in mice receiving AAV expressing IFNγ. Expression of IFNγ through AAV 
successfully induced an M1 phenotype at 4 months that transitioned to a mixed 
phenotype by 6 months. This transition also appeared with an increase in Aβ 
burden suggesting that a mixed phenotype, or enhanced expression of M2a and 
M2c markers, could contribute to increasing Aβ burden and disease progression.  
Introduction  
First described by Alois Alzheimer in 1907, Alzheimer’s disease (AD) is a 
progressive, neurodegenerative disease characterized pathologically by the 
presence of amyloid plaques formed by amyloid-beta (Aβ) peptide aggregates 
and neurofibrillary tangles composed of hyperphosphorylated and aggregated 
tau protein (4). Alois Alzheimer also described inflammation in the form of 
microglia surrounding Aβ plaques. Numerous studies have shown that microglial 
activation results from a reaction to Aβ in AD (205-208). The overall role of 
neuroinflammation in AD remains relatively unknown. 
Peripheral macrophages have been extensively characterized and shown 
to have distinct phenotypes dependent on their stimuli. The M1 phenotype, or 
classical activation, is associated with defense and attack and induces the 
release of pro-inflammatory cytokines such as interleukin 1-beta (IL-1β), tumor 
necrosis factor alpha (TNFα), interleukin 12 (IL-12) and interleukin 6 (IL-6) (79, 
209). The M2 phenotypes are termed alternative activation and include the M2a, 
M2b and M2c states. The M2a phenotype is characterized by wound healing and 
high levels of arginase 1 (ARG1) and the chitinase-like protein YM1 (210). The 
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M2b phenotype is a combination of an M1 and M2a state and is associated with 
high levels of CD86 and the Fc gamma receptors 1 and 3 (FcγR1 and FcγR3) 
(210). Finally, the M2c phenotype is a deactivation state accompanied by high 
levels of transforming growth factor beta (TGFβ) and sphingosine kinase 1 
(SPHK1) (79, 211). It has more recently been shown that microglia are also 
capable of expressing most, if not all, of these inflammatory mediators under the 
correct conditions. 
 The interferon family of cytokines is increased in human AD tissue and in 
the APP/PS1 mouse model and interferon gamma (IFNγ) is the main stimulant for 
microglia to produce an M1 phenotype by binding its receptor, increasing 
STAT1α, and increasing transcription of several M1 cytokine genes (212, 213). 
Some studies have used IFNγ to induce an M1 phenotype, with one study 
showing classical activation of microglia produces a decrease and another 
reporting an increase in Aβ burden (214, 215). Other studies have shown that 
inducing an M1 neuroinflammatory phenotype by introducing TNFα, IL-1β, or 
lipopolysaccharide (LPS) into the brain lowers Aβ burden (83, 88, 216, 217). 
However, these studies do not measure or track the different neuroinflammatory 
phenotypes along with the changes in Aβ burden over long periods of time. 
Additionally, engaging the immune system in the brain using anti-Aβ 
immunotherapy has been shown to be extremely efficacious in lowering Aβ load 
by increasing levels of pro-inflammatory cytokines (29, 38). 
 To better understand the long-term effects of an M1 neuroinflammatory 
phenotype, we bilaterally injected an adeno-associated viral (AAV) vector 
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expressing IFNγ into the frontal cortex and hippocampus of wildtype and 
APP/PS1 mice to induce an M1 phenotype and determine the effects on Aβ 
levels at 4 and 6 months after injection. We hypothesize that a long-term pro-
inflammatory phenotype will lead to decreased levels of Aβ. We found that IFNγ 
induced an M1 phenotype at 4 months but transitioned to include an M2 
phenotype by 6 months. The transition from an M1 to a mixed phenotype did not 
ameliorate Aβ levels at 6 months. Instead, Aβ levels were significantly higher, 
suggesting that a mixed phenotype could accelerate the disease process. 
Methods 
Animals: Female and male wildtype (WT) and APP/PS1 transgenic mice 
(C57BL6 mice carrying human APPSwe and PS1-dE9 mutations) (170) were 
bred in house and aged 3-4 months. Mice were randomly placed into one of eight 
groups based on adeno-associated virus serotype 8 (AAV-8) injection, genotype 
and survival: Fifteen wildtype mice were assigned to receive either AAV-8 
expressing GFP (GFP-AAV) for 4 (N=2F, 1M) or 6 (N=3F, 3M) as a control, or 
AAV-8 expressing IFNγ (IFNγ-AAV) for 4 (N=2F, 1M) or 6 (N=2F, 1M) months. 
Twenty APP/PS1 mice were assigned to receive either GFP-AAV for 4 (N=2F, 
2M) or 6 (N=4F, 4M) for a control, or IFNγ-AAV for 4 (N=2F, 1M) or 6 (N=2F, 3M) 
months.  This study was approved by the University of Kentucky Institutional 
Animal Care and Use Committee and conformed to the National Institutes of 
Health Guide for the Care and Use of Animals in Research.  
AAV preparation: The vector for preparing recombinant AAV was constructed 
by ligating the 1349 bp EcoRI/SalI fragment carrying the IRES-GFP from 
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pSMPUW-IRES-GFP (Cell Biolabs, San Diego, CA) into EcoRI/SalI-digested 
pZac2.1 (gift of Dr. Paul Murphy, University of Kentucky) to create ViCo1.28. The 
IFNγ insert was prepared by polymerase chain reaction amplification of cDNA 
clones obtained from Open Biosystems (GE Healthcare, Dharmacon RNAi and 
gene expression, Piscataway, NJ). The IFNγ PCR primer sequence used was 
CCCGCTAGCTCTGAGACAATGACCACCGCGGACCCCGAATCAGCAGCGA. 
The Open Biosystems Catalogue number for the sequence is MMM1013-
99829104. The clone ID is 8733812 and the accession is BC119063. The 
primers introduced an NheI site at the 5’-end and aSacII site at the 3’-end of the 
IFNγ gene to facilitate cloning into the corresponding sites in ViCo1.28. The 
fidelity of each clone was confirmed by DNA sequence analysis.  
  AAV8 coat protein-pseudotyped AAV2 viruses were prepared by co-
transfecting 10 T225 culture flasks of 293LTV cells (Cell Biolabs, San Diego, CA) 
with 250µg pAAV2/8 (obtained from the University of Pennsylvania Viral Core), 
500µg pAd∆F6 (gift of Dr. Paul Murphy, University of Kentucky) and, 
individually, 250µg of each cytokine clone using 5mg polyethyleneimine to 
enhance DNA uptake. After three days, the cells were harvested, washed, 
suspended in 13ml 150mM NaCl, 50mM Tris·Cl pH 8.4, 0.5% deoxycholate and 
50U/ml of benzonase and incubated at 37°C for 30 min. An additional 2.8ml 5M 
NaCl was added and the incubation was continued for another 30 min. at 45°C. 
The cell suspension was then subjected to four freeze/thaw cycles (30 min at -
80°C/30 min at 45°C). The lysate was then partially clarified by centrifugation at 
18,500xg for 10 min at 20°. The supernatant was laid on top of an iodixanol step 
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gradient and centrifuged at 350,000xg for 1 hour at 18°C. The interface between 
the 40% and 54% iodixanol layers was withdrawn and spin-purified and 
concentrated using four washes with PBS in an Amicon Ultra-15 100,000 MWCO 
spin concentrator. The virus preparation was then titered using real-time PCR 
with primers directed against the CMV promoter region of the DNA encapsulated 
in the virions.  
Bilateral intracranial injection: On the day of surgery, mice were anesthetized 
with isoflurane and placed into a stereotaxic apparatus (51733D digital dual 
manipulator mouse stereotaxic frame, Stoelting Co. Wood Dale, IL). A 
midsaggital incision was used to expose the skull.  Using a dental drill mounted 
on the stereotaxic frame, a total of four burr holes were made. One hole for each 
frontal cortex and hippocampus. The following coordinates were used from 
bregma: frontal cortex, anteroposterior, +2.0mm, lateral +/- 2.0mm; 
hippocampus, anteroposterior -2.7mm, lateral +/- 2.5mm which have been 
previously established by the laboratory using dye injections to confirm 
appropriate placement. A 26 gauge needle attached to a 10µL Hamilton syringe 
(Hamilton, Reno, NV) containing the AAV at a concentration of 2 x 109 genomes / 
µl to be injected was lowered 3.0mm ventral to bregma, and a 2µL injection was 
made over a 4 minute period. The incision was cleaned and sutured. Sutures 
were removed two weeks after surgery. The virus was injected at the maximum 
titer possible based on the concentration supplied so as to achieve the greatest 
expression of IFNγ. 
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Tissue processing: After injection with a lethal dose of Beuthanasia-D, mice 
were perfused intracardially with 25mL of normal saline. Brains were removed 
rapidly and bisected in the midsaggital plane. The left side of the brain was 
immersion fixed in 4% paraformaldehyde. The right side was dissected with the 
frontal cortex and hippocampus being isolated and flash frozen in liquid nitrogen 
and then stored at -80˚C. The left hemibrain was passed through a series of 10, 
20 and 30% sucrose solutions for cryprotection. Using a sliding microtome, 25µm 
frozen horizontal sections were collected and stored free floating in 1XDPBS 
containing sodium azide at 4˚C.  
Immunohistochemistry: Six floating sections spaced 300µm apart spanning the 
injection site (1800µm-3600µm ventral to bregma) were immunostained by using 
commercially available antibodies against Aβ (Rabbit polyclonal Aβ1-16, Life 
Technologies, Carlsbad, CA), CD11b (Rat monoclonal, AbD Serotec, Raleigh, 
NC), and GFAP (Rabbit polyclonal, Dako, Denmark).  Immunohistochemistry was 
performed as previously described (218). Briefly, sections were quenched for 
endogenous peroxidase, blocked and permeabalized. They were then incubated 
overnight in primary antibody at 4oC.  (Aβ 1:3000, CD11b 1:3000, GFAP 
1:10000). After washing, sections were incubated for two hours in the appropriate 
biotinylated secondary antibody (goat anti-rabbit IgG for Aβ and GFAP, goat anti-
rat for CD11b, all 1:3000) (Vector Laboratories, Burlingame, CA). Sections were 
then washed and incubated for one hour in ABC. For CD11b and GFAP, color 
development was performed using the DAB substrate kit with Nickel (Vector 
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Laboratories, Burlingame, CA). For Aβ, color development was performed using 
powder DAB (Sigma, St. Louis, MO)  
Stained sections were mounted, air dried overnight, dehydrated and 
coverslipped in DPX (Electron Microscopy Sciences, Hatfield, PA). 
Immunohistochemical analysis was performed by measuring percent area 
occupied by positive stain using the Nikon Elements BR image analysis system 
(Melville, NY) as described previously (94).  
Quantitative RT-PCR: The Trizol plus RNA purification system (Life 
Technologies, Carlsbad, CA) was used to extract RNA from the frozen right 
hippocampus according to the manufacturer’s instructions. RNA was quantified 
using the Biospec nano spectrophotometer (Shimaduz, Japan). cDNA was 
produced using the cDNA High Capacity kit (Life Technologies, Carlsbad, CA) 
according to the manufacturer’s instructions. Real-time PCR was performed 
using the Fast TaqMan Gene Expression assay (Life Technologies, Carlsbad, 
CA). In each well of a 96 well plate, 0.5µL of cDNA (100ng, based on the RNA 
concentrations) was diluted with 6.5µL of RNase-free water. One microliter of the 
appropriate gene probe was added along with 10µL of the Fast TaqMan to each 
well. Target amplification was performed using ViiA7 (Applied Biosystems, Grand 
Island, NY). The thermal cycling conditions include a holding stage at 95˚C 
followed by 40 cycles of denaturation at 95˚C for 1 second and annealing/primer 
extension at 60˚C for 20 seconds. All genes were normalized to 18S rRNA. We 
determined the fold change for mice receiving IFNγ-AAV compared with mice 
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receiving GFP-AAV using the –∆∆Ct method (219). Table 2.1 shows the genes 
tested along with their PMID and Taqman ID. 
ELISA measurement: Protein for Aβ and IFNγ analysis was extracted from the 
right frontal cortex in 1XDPBS with complete protease and phosphatase inhibitor 
(Pierce Biotechnology Inc., Rockford, IL). The samples were centrifuged at 
10000xg at 4˚C for 15 minutes. The supernatant was removed and labeled the 
“soluble” extract. The pellet was homogenized in 250µL of 70% formic acid and 
centrifuged at 47000rpm at 4˚C for 1 hour. The supernatant was removed and 
neutralized 1:20 with 1M Tris-HCl and brought to a pH of 7 with HCl. This was 
labeled the “insoluble” extract. Protein concentrations for the soluble and 
insoluble extracts were determined using the BCA protein assay kit (Pierce 
Biotechnology Inc., Rockford, IL) according to the manufacturer’s instructions. 
The Meso-Scale Discovery multiplex ELISA system was used to measure Aβ1-38, 
Aβ1-40, and Aβ1-42 levels in the soluble and insoluble extracts (MSD, 
Gaithersburg, MD). The Meso-Scale Discovery Mouse Proinflammatory 7-Plex kit 
(MSD, Gaithersburg, MD) was used to measure IFNγ levels in the soluble extract. 
All steps were followed according to the manufacturer’s directions except for the 
sample incubation time, which was left overnight.  
Analysis: Data are presented as mean ± standard error (SEM). We used two-
way analysis of variance (ANOVA) based on factors treatment (GFP-AAV or 
IFNγ−AAV injection) and survival time (4 or 6 months) to evaluate main effects 
and treatment-by-time interaction within genotype (WT and APP/PS1). No 
statistical comparisons were made across genotype. Because treatment effects 
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at each time point were of interest a priori, data are presented by treatment and 
time point whether or not the treatment-by-time interaction is significant. 
Due to a high proportion of zero values, we used nonparametric two-way 
 ANOVA on ranks to evaluate distributional differences in ELISA-determined 
IFNγ protein levels. Similarly, we used two-way ANOVA on ranks to evaluate 
differences in gene expression (measured by fold change from GFP) as these 
data did not meet parametric ANOVA assumptions. Ranks were assigned using 
the RANK procedure, and ANOVA was performed using the GLM procedure in 
SAS/STAT 9.3® (SAS, Cary, NC). Statistical significance was set at P<0.05.    
Results 
To determine that the IFNγ-AAV resulted in expression of IFNγ we 
performed ELISA measurement. Measurement of IFNγ in the protein extracted 
from the right frontal cortex showed a significant treatment effect such that mice 
injected with IFNγ-AAV had a 5000-fold increase in IFNγ levels at 4 and 6 months 
in both WT and APP/PS1 mice compared to mice receiving GFP-AAV (Figure 
2.1). IFNγ levels within treatment groups were not different at 6 months 
compared to 4 months in WT or APP/PS1 mice.   
To determine the neuroinflammatory phenotype, right hippocampal RNA 
was isolated and real time RT-PCR was performed for several genes specific to 
an M1, M2a, M2b, or M2c macrophage phenotype. Data are shown as fold 
change compared to GFP-AAV at each time point for each genotype. The GFP-
AAV mice showed no significant change in neuroinflammation over time (data not 
shown). Overall, both WT and APP/PS1 mice responded to the IFNγ-AAV with a 
 45 
robust M1 response. IL-12b was increased in IFNγ-AAV treated mice at 4 and 6 
months in both genotypes, and IL-1β was increased at all time points except 4 
months in APP/PS1 (Figure 2.2A-D). Additionally, IL-6 and IL-12a showed 
significant increases at the 6-month (but not 4 month) time points in both WT and 
APP/PS1 mice (Figure 2.2B and D). At the 6-month time point, but not at the 4-
month time point, M2a gene YM1 was significantly increased in WT and 
APP/PS1 mice (Figure 2.2A-D). Also of note are increased M2b markers CD86, 
FcγR1 and FcγR3 and M2c markers TGFβ and SPHK1 at the 6-month time point 
(Figure 2.2B and D). Table 2.2 shows the fold change values for GFP-AAV and 
IFNγ-AAV treated mice. Interestingly, while it may appear that the APP/PS1 mice 
are less responsive to the IFNγ-AAV, it is actually due to the fact that APP/PS1 
mice normally have an inflammatory response to the Aβ deposits in the brain and 
so the fold change achieved by the IFNγ-AAV is less than in WT.  
Next, assessment of CD11b immunohistochemistry in the frontal cortex 
(images not shown) and the hippocampus (dentate gyrus shown, Figure 2.3A-H) 
was performed to determine the effect of IFNγ on microglia. In all four brain 
regions measured, for both WT and APP/PS1 mice receiving IFNγ-AAV, there 
were statistically significant increases in CD11b staining, as measured by 
percent area occupied by positive immunostain, at 6 months compared to 4 
months that were not observed in mice receiving GFP-AAV (i.e., the treatment-
by-time interaction is significant). In the frontal cortex, there was a statistically 
significant increase in microglial staining at 6 months but not 4 months in both 
WT and APP/PS1 mice injected with IFNγ-AAV compared to mice receiving GFP-
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AAV (Figure 2.3I). At 6 months in WT mice, there were significant increases in 
staining in the CA1, CA3 and DG regions (Figure 2.3A-D, and I). APP/PS1 mice 
receiving IFNγ-AAV only showed modest, non-significant increases at 4 months 
(Figure 2.3E, F and I) but significant increases were observed in all hippocampal 
regions by 6 months (Figure 2.3G, H and I).  
 Evaluation of astrogliosis using GFAP immunohistochemistry was also 
performed on the frontal cortex (images not shown) and the hippocampus 
(dentate gyrus shown, Figure 2.4A-H). Distribution of GFAP staining in WT 
(Figure 2.4A and C) and APP/PS1 mice (Figure 2.4E and G) receiving GFP-AAV 
was typical for age and genotype (220). Curiously, IFNγ-AAV injection in both the 
WT and APP/PS1 mice resulted in decreased GFAP positive staining. We found 
significantly decreased GFAP staining 4 months after IFNγ-AAV injection in the 
CA1, CA3, and DG regions of WT mice (Figure 2.4A, B and I). There were no 
significant changes in GFAP staining in the CA1, CA3, or DG regions in the 
APP/PS1 mice at 4 months (Figure 2.4E, F and I). At 6 months, there was a 
significant decrease in astrocyte staining in the CA1, CA3 and DG regions in WT 
(Figure 2.4C, D and I) and in the DG in APP/PS1 mice (Figure 2.4G, H and I).  
 Finally, we examined the effect of IFNγ-AAV on Aβ levels in the APP/PS1 
mice. Aβ levels were determined by immunohistochemistry and ELISA analysis. 
Aβ deposition in the GFP-AAV mice showed a typical distribution of APP/PS1 
mice at this age both 4 and 6 months post injection (Figure 2.5A and C). 
Immunohistochemical analysis of the frontal cortex (images not shown) and the 
hippocampus (DG shown, Figure 2.5A-D) shows no significant change in Aβ 
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deposition 4 months post-injection (Figure 2.5A, B and E). But, at 6 months post 
injection, IFNγ-AAV resulted in increased Aβ deposition in the frontal cortex, CA1 
and CA3 regions versus GFP-AAV treated mice. Aβ deposition was elevated 
significantly at 6 months compared to levels at 4 months in mice receiving IFNγ-
AAV in all areas except the DG, where the effect was marginally significant 
(Figure 2.5B, D and E).  
Biochemical detection of Aβ was performed on PBS soluble and insoluble 
(formic acid soluble) protein extracts from the left anterior cerebral cortex. Aβ1-38, 
Aβ1-40 and Aβ1-42 were analyzed by multiplexed ELISA analysis (Table 2.3). IFNγ-
AAV injection significantly increased soluble Aβ1-40 and marginally increased Aβ1-
42 levels at 4 months relative to GFP-AAV injection in APP/PS1 mice (Table 2.3). 
Soluble Aβ1-38, Aβ1-40 and Aβ1-42 levels significantly increased from 4 to 6 months 
in both treatment groups at the same rate (i.e., the treatment-by-time interactions 
were not significant), but treatment group differences at 6 months were not 
significant due to higher variability in the IFNγ-AAV treated mice. Main effects for 
treatment were significant for soluble Aβ1-38, Aβ1-40 and Aβ1-42. No significant 
changes due to treatment or time were observed for insoluble Aβ, with the 
exception of Aβ1-38, where there was a main effect due to time (p=0.024). 
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Figure 2.1 Protein analysis confirms IFNγ overexpression by AAV. IFNγ 
protein levels. ** indicates P<0.01 for IFNγ-AAV compared to GFP-AAV of that 
time point and genotype.  
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Figure 2.2 IFNγ induces an M1 neuroinflammatory phenotype. Relative gene 
expression for genes representative of the M1, M2a, M2b, and M2c phenotypes. 
Data are shown as fold change relative to mice receiving GFP-AAV at the given 
time point and genotype. A) Wildtype mice receiving IFNγ-AAV for 4 months. B) 
Wildtype mice receiving IFNγ-AAV for 6 months. C) APP/PS1 receiving IFNγ-AAV 
for 4 months. D) APP/PS1 receiving IFNγ-AAV for 6 months. * indicates P<0.05 
for IFNγ-AAV compared to GFP-AAV of that time point and genotype. ** indicates 
P<0.01 for IFNγ-AAV compared to GFP-AAV of that time point and genotype. # 
indicates P<0.05 for 4 month IFNγ-AAV compared to 6 month IFNγ-AAV of that 
genotype. ## indicates P<0.01 for 4 month IFNγ-AAV compared to 6 month IFNγ-
AAV of that genotype.  
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Figure 2.3 IFNγ causes an increase in CD11b staining. A-D) Dentate gyrus of 
wildtype mice receiving GFP-AAV or IFNγ-AAV. E-H) Dentate gyrus of APP/PS1 
mice receiving GFP-AAV or IFNγ-AAV. I) Quantification of CD11b in the frontal 
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cortex, CA1, CA3, and DG. ** indicates P<0.01 for IFNγ-AAV compared to GFP-
AAV of that time point and genotype. # indicates P<0.05 for 4 month IFNγ-AAV 
compared to 6 month IFNγ-AAV of that genotype. ## indicates P<0.01 for 4 
month IFNγ-AAV compared to 6 month IFNγ-AAV of that genotype. Scale bar in 
A is for A-H and is equal to 50µm. 
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Figure 2.4. IFNγ causes a decrease in GFAP staining. A-D) Dentate gyrus of 
wildtype mice receiving GFP-AAV or IFNγ-AAV. E-H) Dentate gyrus of APP/PS1 
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mice receiving GFP-AAV or IFNγ-AAV. I) Quantification of GFAP in the frontal 
cortex, CA1, CA3, and DG. * indicates P<0.05 for IFNγ-AAV compared to GFP-
AAV of that time point and genotype. ** indicates P<0.01 for IFNγ-AAV compared 
to GFP-AAV of that time point and genotype. Scale bar in A is for A-H and is 
equal to 50µm. 
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Figure 2.5 IFNγ increases Aβ deposition. A-D) Dentate gyrus of APP/PS1 mice 
receiving GFP-AAV or IFNγ-AAV. E) Quantification of Aβ in the frontal cortex, 
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CA1, CA3, and DG. * indicates P<0.05 for IFNγ-AAV compared to GFP-AAV of 
that time point and genotype. # indicates P<0.05 for 4 month IFNγ-AAV 
compared to 6 month IFNγ-AAV of that genotype. ## indicates P<0.01 for 4 
month IFNγ-AAV compared to 6 month IFNγ-AAV of that genotype. Scale bar in 
A is for A-D and is equal to 50µm. 
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Table 2.1 Genes for RT-PCR. 
Gene of interest PMID Taqman ID 
IL-6 NM_031168.1 Mm.1019 
IL-1β NM_008361.3 Mm.222830 
IL-12a NM_008351.2 Mm.103783 
IL-12b NM_008352.2 Mm.239707 
ARG1 NM_007482.3 Mm.154144 
YM1 (Chil3) NM_009892.2 Mm.387173 
CD86 NM_019388.3 Mm.1452 
FcγR1 NM_010186.5 Mm.150 
FcγR3 NM_010188.5 Mm.22119 
TGFβ1 NM_011577.1 Mm.248380 
SPHK1 NM_011451.3 Mm.20944 
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Table 2.2 Fold change values for RT-PCR. Bolded font indicates P<0.05 
compared to GFP-AAV of that time point and genotype. 
 GFP-AAV IFNγ-AAV WT APP/PS1 WT APP/PS1 
Gene 4 mo 6 mo 4 mo 6 mo 4 mo 6 mo 4 mo 6 mo 
IL-6 1.5 ± 0.51 
1.4 ± 
0.45 
2.46 ± 
1.36 
1.16 ± 
0.21 
5.27 ± 
2.8 
92.42 
± 
81.72 
12.23 
± 7.43 
15.03 
± 5.81 
IL-1β 1.7 ± 0.72 
1.2 ± 
0.27 
1.42 ± 
0.57 
1.15 ± 
0.23 
26.55 
± 8.8 
3673.4 
± 
3599.1 
77.75 
± 
31.53 
96.07 
± 
25.74 
IL-12a 1.62 ± 0.68 
1.25 ± 
0.38 
1.75 ± 
0.79 
1.4 ± 
0.44 
3.62 ± 
1.9 
29.53 
± 0.43 
5.37 ± 
3.92 
89.85 
± 
60.30 
IL-12b 1.37 ± 0.94 
1.29 ± 
0.39 
1.14 ± 
0.43 
1.68 ± 
0.76 
108.96 
± 
36.47 
109.55 
± 
79.82 
128.58 
± 
103.11 
239.43 
± 
77.25 
ARG1 1.95 ± 0.79 
1.19 ± 
0.34 
1.41 ± 
0.45 
1.88 ± 
0.75 
0.55 ± 
0.09 
1.68 ± 
0.30 
0.49 ± 
0.12 
2.02 ± 
0.36 
YM1 1.87 ± 1.06 
1.08 ± 
0.19 
1.31 ± 
0.51 
2.35 ± 
1.17 
2.91 ± 
1.12 
184.47 
± 
174.22 
6.48 
±4.07 
68.66 
± 
23.88 
CD86 1.21 ± 0.3 
1.56 ± 
0.66 
1.09 ± 
0.22 
1.3 ± 
0.93 
21.2 ± 
4.97 
24.9 ± 
4.51 
66.85 
± 
43.23 
19.93 
± 7.52 
FcγR1 1.2 ± 0.28 
1.10 ± 
0.24 
1.12 ± 
0.26 
1.36 ± 
0.55 
13.45 
± 3.05 
59 ± 
34.83 
9.11 ± 
2.61 
18.44 
± 2.65 
FcγR3 1.49 ± 0.46 
1.05 ± 
0.15 
1.14 ± 
0.31 
1.27 ± 
0.44 
4.9 ± 
0.83 
36.28 
± 
10.41 
4.89 ± 
1.61 
13.64 
± 1.17 
TGFβ1 1.45 ± 0.61 
1.29 ± 
0.40 
1.07 ± 
0.19 
1.23 ± 
0.26 
1.58 ± 
0.33 
3.53 ± 
0.83 
1.95 ± 
0.28 
1.95 ± 
0.74 
SPHK1 2.01 ± 1.28 
1.07 ± 
0.18 
1.46 ± 
0.60 
1.58 ± 
0.77 
0.06 ± 
0.02 
8.23 ± 
2.69 
0.19 ± 
0.03 
2.21 ± 
0.28 
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Table 2.3 Soluble and insoluble Aβ levels measured by ELISA. Bolded font 
indicates p<0.05 compared to GFP-AAV of the same time point. 
 Soluble (pg/µg protein) Insoluble (pg/µg protein) 
AAV 
Injection 
Survival 
(months) Aβ1-38 Aβ1-40 Aβ1-42 Aβ1-38 Aβ1-40 Aβ1-42 
GFP-
AAV 4 
1.67 ± 
0.77 
2.97 ± 
0.28 
12.90 ± 
2.24 
9.04 ± 
1.99 
98.70 ± 
36.77 
903.27 
± 56.1 
GFP-
AAV 6 
3.16 ± 
0.75 
5.10 ± 
0.44 
25.37 ± 
3.81 
23.82 ± 
2.83 
335.53 
± 64.95 
1634.87 
± 397.9 
IFNγ-
AAV 4 
3.68 ± 
0.23 
5.41 ± 
0.91 
27.17 ± 
4.94 
20.56 ± 
8.48 
295.78 
± 87.63 
2855.26 
± 
1267.9 
IFNγ-
AAV 6 
4.95 ± 
0.51 
6.57 ± 
0.89 
38.90 ± 
7.35 
27.10 ± 
4.10 
269.72 
± 55.2 
2047.32 
± 436.0 
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Discussion 
Alzheimer’s disease, while characterized by Aβ plaques and neurofibrillary 
tangles, is associated with a robust neuroinflammatory response. Using the 
macrophage classification system of M1, M2a, M2b and M2c (79, 209) we 
recently showed that the neuroinflammatory state is highly variable in the early 
stages of Alzheimer’s disease (95). This variability was apparent in a population 
that were clinically and pathologically indistinguishable suggesting that 
neuroinflammation may be a source of variability in the Alzheimer’s population. 
Furthermore, we hypothesize the neuroinflammatory state will influence 
progression of the disease and also response to therapeutic interventions. To 
better determine the role these distinct neuroinflammatory phenotypes have on 
Aβ pathology, we developed AAV vectors to express IFNγ, the initiator of an M1 
neuroinflammatory state (221, 222), with the goal of chronically polarizing the 
state of the brain to an M1 state. We then injected this into the brains of 
APP/PS1 mice and examined their pathological progression 4 and 6 months 
post-injection. Overall, our data suggest that while initially we did polarize the 
phenotype to M1, by 6 months the neuroinflammatory phenotype showed a 
combination of M1 and M2. Aβ deposition was unaffected by the M1 phenotype 
but increased when the combination of inflammatory markers were increased. 
Whether this increase in Aβ is due to the M2 phenotypes direct actions or indirect 
actions on the M1 microglia remains unclear.  
 Macrophage activation can be categorized as M1, M2a, M2b and M2c. M1 
is characterized by high IL-12 and low IL-10 while the M2 phenotypes are 
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characterized by high IL-10 and low IL-12 (210). Additionally, M1 macrophages 
express high levels of IL-1β, TNFα and IL-6 (79). M2a macrophages are 
associated with wound healing and repair gene expression including YM1 and 
ARG1 (210). The M2b phenotype is very much like an M1 phenotype with the 
exception of the IL-10/IL-12 balance and high expression of CD86 (210). Finally, 
the M2c state is characterized by high TGFβ and SPHK1 (79, 211). IFNγ, with 
and without LPS or TNFα, is the typical M1 phenotype stimulus (221, 222). Using 
BV2 microglial cell cultures, we have previously shown that treatment of BV2 
cells with IFNγ results in an M1 phenotype (80). We hypothesized that a 
continuous presence of IFNγ would chronically polarize the inflammatory state of 
the brain to an M1 state. We found that expression of IFNγ through intracranial 
injection of IFNγ-AAV successfully induced an M1 phenotype at 4 months post-
injection, but over time this transitioned to a combined M1 and M2 phenotype by 
6 months. Both the early M1 phenotype and the 6 month transition to a mixed 
phenotype were present in both wildtype and APP/PS1, indicating that the 
APP/PS1 mice and wildtype mice responded similarly to the IFNγ-AAV injection.  
CD11b (CR3) has been used as one of a handful of microglial activation 
markers. In the mouse, CD11b labels all ramified, resting microglia while GFAP 
labels astrocytes and the intensity of the staining is generally increased with 
inflammatory stimuli (220, 223, 224). There is an assumption in the field that 
microglial activation and astrogliosis correspond to high levels of pro-
inflammatory cytokines such as IL-1β and IL-6. In the current study, we find that 
CD11b immunostaining is not affected by the IFNγ-AAV injection at the 4 month 
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time point, when the neuroinflammatory state is primarily M1, but is only 
increased when M2 markers are also increased. We also find that GFAP staining 
decreases when M2 markers increase even though M1 genes are still high. 
These data suggest that more careful analysis of neuroinflammatory markers is 
necessary for appropriate interpretation of data. The CD11b data here would 
indicate that inflammation is only increased at the 6 month time point, yet, we see 
that at the 4 month time point IL-1β and IL-12 are significantly elevated.  
The role of neuroinflammation on Aβ deposition remains controversial. 
Studies with LPS injection have shown both decreases and increases in Aβ with 
neuroinflammation (83, 217, 225). Additionally, microglial “activation” has been 
linked to both increased and decreased Aβ loads (223, 225). Our goal in this 
study was to determine the influence of an M1 neuroinflammatory phenotype on 
Aβ deposition. At the 4 month time-point, when M1 neuroinflammation 
predominates in the brains of mice injected with IFNγ-AAV, Aβ deposition 
appears unaffected with no significant difference between IFNγ-AAV and GFP-
AAV injected mice. We do find increased Aβ deposition at the 6 month time point 
but this is in the presence of a mixed neuroinflammatory phenotype. At this time-
point we see not only M1 markers including IL-12, IL-1β and IL-6, but also M2a 
marker YM1. This is not the first time that M1 markers have been associated with 
unchanging, or decreased Aβ deposition (215). Indeed, anti-Aβ immunotherapy 
initiates activation of M1 markers (89). Furthermore, we have previously shown 
that lithium treatment results in unchanging biochemical levels of Aβ but 
increased Aβ deposition accompanied by increased expression of M2a markers 
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YM1, ARG1 and IL-1 receptor antagonist (94). In this study we also see relatively 
unchanging biochemical levels of Aβ, increased Aβ deposition shown by an 
increase in Aβ staining and an increase in the expression of M2a markers at 6 
months. This increase in Aβ staining at 6 months implies that a mixed 
neuroinflammatory phenotype increases Aβ burden. While the mechanism is 
unclear, it appears that an M2a phenotype promotes Aβ deposition in the 
absence of changing total Aβ levels. Future studies will attempt to elucidate the 
mechanism of this phenomenon.  
Human data from Alzheimer’s patients also shows a similar trend in 
neuroinflammatory switching. Our lab has previously shown that in early AD, 
patients are polarized towards either an M1 or an M2a phenotype (95). By end-
stage AD, patients have a combined M1, M2a and M2c phenotype. Also, early 
AD patients polarized towards an M2a phenotype had an increased neuritic 
plaque load compared to those polarized towards an M1 phenotype. This 
suggests that the transition to a mixed phenotype is associated with disease 
progression and increased Aβ burden. Future studies on the effects of the 
neuroinflammatory phenotypes, especially an M2 phenotype, could provide 
possible therapeutic targets for AD progression and potential biomarkers to 
determine the stage of AD. 
Conclusions 
Expression of IFNγ through AAV successfully induced an M1 phenotype at 4 
months that transitioned to a mixed phenotype by 6 months. This transition also 
appeared with an increase in Aβ burden suggesting that a mixed phenotype, or 
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enhanced expression of M2a and M2c markers, could contribute to increasing Aβ 
burden and disease progression.  
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Hyperhomocysteinemia induced gene expression changes in astrocytes, 
microglia, endothelial cells and neurons 
Erica M. Weekman1,2, Abigail E. Woolums1, Tiffany L. Sudduth1, and Donna M. 
Wilcock1,2* 
1Sanders-Brown Center on Aging, 2Department of Physiology, University of 
Kentucky, Lexington, Kentucky, United States of America 
Abstract 
High levels of homocysteine, termed hyperhomocysteinemia, is a risk factor for 
vascular cognitive impairment, which is the second leading cause of dementia. 
While hyperhomocysteinemia induces microhemorrhages and cognitive decline 
in mice, the effects of hyperhomocysteinemia on each cell type remains 
unknown. Therefore, we determined the gene expression changes of separate 
cell cultures of astrocytes, microglia, endothelial cells and neurons after 
treatment with high levels of homocysteine for 24, 48, 72 and 96 hours. 
Astrocytes showed decreased levels of several potassium channels and 
aquaporin 4 up to 72 hours and an increase in matrix metalloproteinase 9 at 48 
hours. Gene changes in microglia indicated an initial pro-inflammatory response 
at 48 hours, which transitioned to an anti-inflammatory response by 72 hours. 
Endothelial cells showed a disruption in several tight junction proteins at 72 hours 
and neurons had gene changes in kinases and phosphatases as well as changes 
in potassium channel gene expression. Overall, this data provides insight into the 
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specific effects of high levels of homocysteine and offers several possible 
therapeutic targets for vascular cognitive impairment. 
Introduction 
Homocysteine is a non-protein forming amino acid involved in the production of 
both methionine and cysteine. Mutations in the methylenetetrahydrofolate 
reductase or cystathionine beta synthase genes, or low levels of vitamins B6, B9 
and B12 cause increased levels of plasma homocysteine (199, 226-229), termed 
hyperhomocysteinemia (HHcy). HHcy is a risk factor for both vascular cognitive 
impairment and dementia (VCID) and Alzheimer’s disease (AD) (185, 186, 230); 
however, the mechanism of how HHcy leads to VCID or AD remains unknown. 
 Our lab has been working on HHcy induction in mice as a model of VCID. 
Alone, dietary HHcy induction through deficiency in vitamins B6, B9 and B12 and 
enrichment in methionine results in cognitive impairment, microhemorrhages, 
reduced cerebral blood flow and neuroinflammation (203). Induction of HHcy in 
APP/PS1 mice produces a co-morbidity mouse model producing aspects of both 
AD and VCID (204). The co-morbidity mouse model displayed additive cognitive 
deficits on the radial arm water maze. They also displayed significant increases 
in microglial staining and a switch from an anti-inflammatory phenotype to a pro-
inflammatory phenotype. While there weren’t significant changes in total 
Aβ levels, we did see a change in the location of Aβ, with more accumulating 
around the vasculature. We also saw a significant increase in microhemorrhages 
and matrix metalloproteinase 9 (MMP9) and MMP2 activity.  
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It has been unclear, from our in vivo studies, what the effects of 
homocysteine are on the individual cell types of the brain, which could help us 
elucidate possible therapeutic targets. To determine the cell specific effects of 
HHcy, we took separate cultures of C8-D1A astrocytes, BV2 microglia cells, N2a 
neurons and primary endothelial cells and treated them with 50µM of 
homocysteine for 24, 48, 72 and 96 hours. For each cell type, we analyzed the 
gene expression of several cell type specific markers, inflammatory markers and 
MMP9 system markers.  
Methods 
C8-D1A cell culture: C8-D1A cells were obtained directly from American Type 
Culture Collection (Catalogue No. CRL-2541, Manassas, VA). Cells were grown 
in 75 cm2 flasks in DME media containing 10% fetal bovine serum and 1% 
penicillin-streptomycin (Life Technologies, Carlsbad, CA) until approximately 
80% confluency was reached, usually after 7 days. 
BV2 cell culture: BV2 cells, originally developed by Elisabetta Blasi (231), 
(courtesy of Dr. Linda Van Eldik) were grown in petri dishes in FX12 media 
containing 10% fetal bovine serum, 1% serum L-glutamate, and 1% penicillin-
streptomycin (Life Technologies, Carlsbad, CA) until approximately 80% 
confluency was reached, usually after 3 days.   
Primary endothelial cell culture: C57BL/6 mouse primary brain microvascular 
endothelial cells were obtained directly from Cell Biologics (Catalogue No. C57-
6023, Chicago, IL). Cells were grown in 75 cm2 flasks coated with a gelatin based 
coating solution (Cell Biologics, Chicago, IL). Endothelial cell media containing 
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vascular endothelial growth factor, endothelial cell growth supplement, heparin, 
epidermal growth factor, hydrocortisone, L-glutamine, an antibiotic-antimycotic 
solution and fetal bovine serum (Complete Mouse Endothelial Cell Medium w/ 
Kit, Cell Biologics, Chicago, IL) was used to grow the endothelial cells to 
approximately 80% confluency. 
N2a cell culture: N2a cells (courtesy of Dr. John Gensel) (232) were grown in 75 
cm3 flasks in Optimem media containing 40% DME media, 10% fetal bovine 
serum, and 1% penicillin-streptomycin (Life Technologies, Carlsbad, CA) until 
approximately 80% confluency was reached, usually after 3 days.   
HHcy treatment: Once the cells reached 80% confluency, the cells were 
trypsinized and re-suspended in 10mL of serum-free media. For the BV2 and 
N2a cells, 100µl of cells were placed in each well of a 6 well plate. For the C8-
D1A cells, 500µL of cells were placed in each well of a 6 well plate. For the 
endothelial cells, 1mL of cells were placed in a 25cm2 flask coated with a gelatin 
based coating solution. For all cells, the volume in each well or flask was brought 
up to 2mL. No obvious cell death occurred while the cells were in serum free 
media. Once the cells reached 60-70% confluency, media was replaced with 
either serum-free media as the no-treatment control or 50µM homocysteine 
solution (Sigma, St. Louis, MO) in serum-free media, which is a moderate level of 
hyperhomocysteinemia. Cells were incubated at 5% CO2 at 37° for 24, 48, 72, 
and 96 hours before removal. Media was aspirated and cells were rinsed in 1X 
DPBS (Life Technologies, Carlsbad, CA) and frozen at -20° until RNA isolation.  
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Cell treatments were run at least twice for each cell line in groups of two or three 
(N=4-6 per group). 
Quantitative RT-PCR: Cell RNA was extracted from the frozen cells using cells 
scrapers in RLT buffer from the RNeasy Mini-kit (Qiagen, Valencia, CA). The 
subsequent steps of the extraction were done according to the manufacturer’s 
instructions. The Biospec-Nano Spectrophotometer (Shimadzu, Kyoto, Japan) 
was used to quantify the nucleic acid concentration of each sample. cDNA was 
produced using the High Capacity kit (ThermoFisher, Walthan, MA) according to 
the manufacturer’s instructions. The cDNA was produced using the Veriti™ 96-
well Thermocycler (Applied Biosystems, Grand Island, NY) through heating and 
annealing cycles. 
 RT-PCR was performed using the Fast-TaqMan Gene Expression kit (Life 
Technologies, Carlsbad, CA) in 96-well plates. In each well, 1µL of the 
appropriate gene probe (Life Technologies, Carlsbad, CA) listed in Table 3.1 was 
added to 10µL of the Fast-TaqMan reagent along with 0.5µL of cDNA and 6.5µL 
of RNAse-free water for a final volume of 18µL. Real-time RT-PCR was 
performed using the ViiA™7 Real Time PCR system (Applied Biosystems, Grand 
Island, NY). All genes were normalized to the 18S rRNA gene. Fold change was 
determined using the –∆∆Ct method and the homocysteine treated cells were 
compared to the control cells of the appropriate time point.  
Analysis: Data are presented as mean ± SEM. Statistical analysis was 
performed using the JMP statistical analysis software program (SAS Institute, 
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Cary, NC). Student’s t-test were performed and statistical significance was 
assigned when the P-value was <0.05. 
Results 
Astrocytes: Astrocytes treated with homocysteine show a trend for decreased 
aquaporin 4 (AQP4) levels up to 72 hours and then increase again at 96 hours; 
however this was not significant when compared to controls (Figure 3.1A). Glial 
fibrillary acidic protein (GFAP) levels increased up to 72 hours and then 
decreased at 96 hours, but again this was not significant when compared to 
controls. The ATP-sensitive inward rectifier potassium channel 10 (KCNJ10) had 
significantly increased gene expression levels at 24 hours when compared to 
controls. However by 48 and 72 hours levels were significantly decreased when 
compared to the 24 hour HHcy treated cells (Figure 3.1B). Levels of KCNJ10 
were significantly increased at 96 hours when compared to 72 hour HHcy treated 
cells.  
 While there were no significant changes in the pro-inflammatory marker 
tumor necrosis factor alpha (TNFα) (Figure 3.1C), there was a significant 
decrease in the anti-inflammatory marker interleukin 1 receptor antagonist 
(IL1Ra) at 48 hours when compared to controls. There was also an overall trend 
for decreased IL1Ra up to 72 hours and then an increase at 96 hours. The other 
anti-inflammatory marker transforming growth factor beta 1 (TGFβ1) was 
increased at 48 hours but decreased at 72 hours. 
 There was a slight increase in MMP3 expression in astrocytes treated with 
homocysteine over the 96 hours, but this was not significant (Figure 3.1E). 
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However, MMP9 expression was significantly increased at 48 hours when 
compared to controls. Levels were significantly decreased again at 72 and 96 
hours when compared to the 48 hour treated homocysteine cells (Figure 3.1F). 
Tissue inhibitor of matrix metalloproteinase 1 (TIMP1) gene expression levels 
increased over time with 96 hours significantly different from controls and 24 and 
48 hour treated homocysteine cells. 
Microglia: Microglia cells treated with homocysteine had an increase in the pro-
inflammatory markers IL1β and TNFα and an increase in the anti-inflammatory 
marker TGFβ1 with peaks at 48 hours (Figure 3.2A). Levels decreased at 72 
hours and again at 96 hours when compared to 48 hour homocysteine treated 
cells (Figure 3.2B). IL1Ra levels were significantly increased at 72 hours 
compared to controls and 48 hour homocysteine treated cells. Levels were 
significantly decreased by 96 hours when compared to 72 hour homocysteine 
treated cells. Cluster of differentiation 86 (CD86) had slight increases up to 72 
hours and a decrease at 96 hours that was significantly different from the 72 hour 
homocysteine treated cells.  
 MMP9 levels were slightly increased at 24 hours but were significantly 
increased at 72 hours when compared to controls (Figure 3.2C) and 24, 48 and 
96 hour homocysteine treated cells (Figure 3.2D). TIMP1 levels were significantly 
increased at 96 hours when compared to controls and 48 and 72 hour 
homocysteine treated cells. 
Endothelial cells: Endothelial cells treated with homocysteine showed no 
changes in platelet endothelial cell adhesion molecule 1 (PECAM1) gene 
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expression levels over the 96 hours (Figure 3.3A). Claudin-5 (CLDN5) levels had 
increasing levels with a peak at 72 hours. Levels were significantly decreased at 
96 hours when compared to 72 hour homocysteine treated cells (Figure 3.3B). 
Occludin (OCEL1) levels were significantly decreased at 48 hours when 
compared to controls but levels were significantly higher at 72 hours when 
compared to 48 and 96 hour homocysteine treated controls. Collagen type IV 
alpha 5 (COL4α5) had decreased levels with a peak at 72 hours. Levels were 
significantly increased at 96 hours when compared to all other homocysteine 
treated cells. 
 While there were no changes in TGFβ1, mannose receptor C type 1 
(MRC1) had slightly increased levels 24 and 48 hours but decreases at 72 and 
96 hours (Figure 3.3C, D). 
 Endothelial cells treated with homocysteine had significantly increased 
levels of MMP3 at 48 hours when compared to controls (Figure 3.3E). However, 
MMP9 levels, while slightly increased at 24 hours, were significantly decreased 
at 48 and 96 hours when compared to 24 hour homocysteine treated cells 
(Figure 3.3F). Levels were returned to normal at 72 hours. TIMP1 was only 
slightly increased at 48 hours with no significant changes. 
Neurons: Neural cells treated with homocysteine had slight increases in amyloid 
precursor protein (APP) and granulin (GRN) at 48 hours but levels decreased at 
72 hours and further decreased at 96 hours (Figure 3.4A). Both glycogen 
synthase kinase 3 beta (GSK3β), serine/threonine-protein phosphatase 2A 
(PPP2CA), and KCNMA1 increased up to 72 hours but decreased at 96 hours 
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when compared to 72 hour homocysteine treated cells (Figure 3.4B). KCNJ10 
had significantly increased levels at 48 hours when compared to controls and 
levels were significantly decreased at 72 hours when compared to 48 hour 
homocysteine treated cells.  
 The pro-inflammatory marker TNFα had increased gene expression at 48 
hours but returned to normal at 72 hours; however, this was not significant 
(Figure 3.4C). All the anti-inflammatory markers (IL1Ra, CD86 and TGFβ1) 
showed increased levels with a significant peak at 72 hours when compared to 
controls. It should be noted that while the fold changes for these inflammatory 
markers are dramatic, the cycle numbers were high, indicating the expression 
level was low in these neural cells. CD86 and TGFβ1 were significantly 
decreased at 96 hours when compared to 72 hour homocysteine treated cells 
(Figure 3.4D).  
 Both MMP9 and TIMP1 only had increases at 72 hours with levels 
returning to normal at 96 hours (Figure 3.4E, F). 
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Figure 3.1 Astrocyte gene expression after HHcy treatment.  
Relative gene expression of (A) astrocyte specific markers, (C) inflammatory 
markers, and (E) MMP9 system markers. Data are shown as a fold change from 
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the control cells at the appropriate time point. * indicates P<0.05, ** indicates 
P<0.01 compared to control cells at the appropriate time point. P values for 
homocysteine treated comparisons for (B) astrocyte specific markers, (D) 
inflammatory markers, and (F) MMP9 system markers. Significant differences are 
shown in bold.  
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Figure 3.2 Microglia gene expression after HHcy treatment.  
Relative gene expression of (A) inflammatory markers and (C) MMP9 system 
markers. Data are shown as a fold change from the control cells at the 
appropriate time point. * indicates P<0.05, ** indicates P<0.01 compared to 
control cells at the appropriate time point. P values for homocysteine treated 
comparisons for (B) inflammatory markers and (D) MMP9 system markers. 
Significant differences are shown in bold. 
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Figure 3.3 Endothelial cell gene expression after HHcy treatment.  
Relative gene expression of (A) endothelial cell specific markers, (C) 
inflammatory markers, and (E) MMP9 system markers. Data are shown as a fold 
change from the control cells at the appropriate time point. * indicates P<0.05 
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compared to control cells at the appropriate time point. P values for 
homocysteine treated comparisons for (B) endothelial specific markers, (D) 
inflammatory markers, and (F) MMP9 system markers. Significant differences are 
shown in bold. 
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Figure 3.4 Neural cell gene expression after HHcy treatment.  
Relative gene expression of (A) neuron specific markers, (C) inflammatory 
markers, and (E) MMP9 system markers. Data are shown as a fold change from 
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the control cells at the appropriate time point. * indicates P<0.05, ** indicates 
P<0.01 compared to control cells at the appropriate time point. P values for 
homocysteine treated comparisons for (B) neuronal specific markers, (D) 
inflammatory markers, and (F) MMP9 system markers. Significant differences are 
shown in bold. 
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Table 3.1 Genes for RT-PCR. 
 
Gene of interest PMID Taqman ID 
IL1β NM_008361.3 Mm.222830 
TNFα NM_013693.3 Mm.1293 
IL1Ra NM_031167.5 Mm.882 
CD86 NM_019388.3 Mm.1452 
TGF1β NM_011577.1 Mm.248380 
MRC1 NM_008625.2 Mm.2019 
MMP3 NM_010809.1 Mm.4993 
MMP9 NM_013599.3 Mm.4406 
TIMP1 NM_001044384.1 Mm.8245 
AQP4 NM_009700.2 Mm.250786 
GFAP NM_001131020.1 Mm.1239 
KCNJ10 NM_001039484.1 Mm.254563 
KCNMA1 NM_001253358.1 Mm.343607 
PECAM1 AK037551.1 Mm.343951 
CLDN5 NM_013805.4 Mm.22768 
OCEL1 NM_008756.2 Mm.4807 
COL4α5 NM_001163155.1 Mm.286892 
APP NM_001198823.1 Mm.277585 
GRN NM_008175.4 Mm.1568 
GSK3β NM_019827.6 Mm.394930 
PPP2CA NM_019411.4 Mm.00479816 
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Discussion 
HHcy is a risk factor for both VCID and AD, the two most common forms of 
dementia. Our lab has developed a mouse model that induces HHcy to model 
VCID. In this mouse model, we see cognitive deficits, an increase in microglial 
staining, a pro-inflammatory phenotype and a significant increase in 
microhemorrhages (203). While we know the overall effect of HHcy on the brain, 
there is limited information on the cell specific effects of HHcy. We took cell 
cultures of astrocytes, microglia, endothelial cells and neural cells and treated 
them with homocysteine to determine gene expression changes. Astrocytes 
showed a decrease in several potassium channels and AQP4 with lows at 72 
hours. Microglia cells showed an initial increase in pro-inflammatory markers at 
48 hours but then an increase in anti-inflammatory markers at 72 hours. 
Endothelial cells showed an increase in claudin-5 up to 72 hours but a decrease 
in occludin. Neural cells treated with homocysteine showed an increase in 
several cell specific markers and anti-inflammatory markers with peaks at 72 
hours.  
 Inflammation has been implicated as a possible mechanism for vascular 
damage in VCID (233) and induction of HHcy in mice to model VCID has shown 
a pro-inflammatory response (203), which can activate MMPs and lead to 
vascular breakdown and cognitive impairment. Inflammation has also been 
implicated in the disease process of AD and our co-morbidity mice show a switch 
from an anti-inflammatory phenotype to a pro-inflammatory phenotype. Both 
microglia and astrocytes are capable of secreting inflammatory cytokines and 
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proteases (234, 235) in response to a variety of different stimuli, thus controlling 
the inflammatory phenotype. When treated with HHcy in vitro, microglia show a 
transition from a pro-inflammatory response at 48 hours to an anti-inflammatory 
response at 72 hours. While our mouse models show a pro-inflammatory 
phenotype when on diet for 6 months, this cell data suggests that long-term 
exposure to HHcy would ultimately result in a switch to an anti-inflammatory 
phenotype. Astrocytes, neural cells and endothelial cells show a limited 
inflammatory response to HHcy with slight increases in anti-inflammatory 
markers around 48 and 72 hours. This shows that only microglia, rather than 
microglia and astrocytes, are the inflammatory phenotype mediators when HHcy 
is present.  
 One of the major proteases involved in tight junction breakdown is MMP9 
(130, 144), which can be activated via inflammation, specifically the pro-
inflammatory cytokines TNFα and IL1β (113, 114). Our VCID mouse model 
shows a significant increase in activation of MMP9 as well as increases in TNFα 
and IL1β, providing a possible mechanism for the increase in microhemorrhages 
(203, 204). At 48 hours, astrocytes and endothelial cells are the major source of 
MMP9 and MMP3, which is the activator of MMP9, respectively. However, at 72 
hours, microglia are the main source of MMP9. Treatment of individual cell types 
with homocysteine has provided insight into the major source of MMP9 at 
different time points.  
 The response of cell specific genes to homocysteine can also generate 
therapeutic targets for treatment of VCID. In astrocytes, AQP4, KCNJ10 and 
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KCNMA1 were decreased, similarly peaking at 72 hours. These potassium 
channels and AQP4 channel are associated with homeostatic control of 
potassium buffering, water balance and are located at the astrocytic end-feet 
(236-238). The decreases seen in these astrocytic end-feet genes could lead to 
disruption of the neurovascular unit and blood flow to these damaged areas, 
contributing to the cognitive decline seen in our mouse model. Endothelial cells 
also play a major role in the neurovascular unit by maintaining the tight junctions 
that make up the blood brain barrier. Interruption of these tight junctions and 
consequently the blood brain barrier can lead to microhemorrhages that damage 
the surrounding brain tissue. Treatment of endothelial cells with homocysteine 
showed a significant disruption in tight junctions as shown by the decrease in 
gene expression of occludin, thus providing another mechanism via which HHcy 
causes microhemorrhages and cognitive decline. HHcy is also a risk factor for 
AD (230), which is characterized by Aβ plaques and tangles made of 
hyperphosphorylated tau (4). Neural cells, the source of hyperphosphorylated 
tau, show increases in the tau kinase GSK3β at 72 hours compared to 24 hours 
and a significant increase in the tau phosphatase PPP2CA at 72 hours. These 
homocysteine induced gene expression changes could lead to changes in tau 
phosphorylation, thus increasing the chance of developing a tauopathy from 
HHcy.  
 The responses of specific cell types to homocysteine provide a wide 
variety of targets for therapeutics. For example, targeting microglia to reduce the 
release of pro-inflammatory cytokines could help reduce MMP9 activation leading 
 84 
to a decrease in tight junction breakdown. Astrocytic end-feet present another 
possible target to help reduce neurovascular damage and cognitive decline. 
GSK3β could also be targeted to help reduce the risk of developing tauopathies 
in HHcy patients. The gene changes seen here have the potential to be 
biomarkers for VCID and when compared to gene changes seen in AD, possible 
biomarkers for patients with VCID and AD. Other future studies would include 
protein expression and activity assays to confirm the gene expression changes. 
While HHcy may alter gene expression, this does not always translate to a 
change in protein levels or changes in activity of the proteins.  
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Kopper2, Oliver W. Phillips, Dave K. Powell3,4, and Donna M. Wilcock1,2* 
University of Kentucky, 1Sanders-Brown Center on Aging, 2Department of 
Physiology, 3Magnetic Resonance Imaging and Spectroscopy Center, 
4Department of Biomedical Engineering, Lexington, KY 40536 USA 
Abstract  
 Vascular cognitive impairment and dementia (VCID) is the second most 
common form of dementia behind Alzheimer’s disease (AD). It is estimated that 
40% of AD patients also have some form of VCID. One promising therapeutic for 
AD is anti-Aβ immunotherapy, which uses antibodies against Aβ to clear it from 
the brain. While successful in clearing Aβ and improving cognition in mice, anti-
Aβ immunotherapy failed to reach primary cognitive outcomes in several different 
clinical trials. We hypothesized that one potential reason the anti-Aβ 
immunotherapy clinical trials were unsuccessful was due to this high percent of 
VCID co-morbidity in the AD population. We used our unique model of VCID-
amyloid co-morbidity to test this hypothesis. We placed 9 month old wildtype and 
APP/PS1 mice on either a control diet or a diet that induces 
hyperhomocysteinemia (HHcy). After being placed on the diet for 3 months, the 
mice then received intraperotineal injections of either IgG2a control or 3D6 for 
another 3 months. While we found that treatment of our co-morbidity model with 
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3D6 resulted in decreased total Aβ levels, there was no cognitive benefit of the 
anti-Aβ immunotherapy in our AD/VCID mice. Further, microhemorrhages were 
increased by 3D6 in the APP/PS1/control, but further increased in an additive 
fashion when 3D6 was administered to the APP/PS1/HHcy mice. This suggests 
that the use of anti-Aβ immunotherapy in patients with both AD and VCID would 
be ineffective on cognitive outcomes.  
Introduction 
Alzheimer’s disease (AD) is the most common form of dementia and is 
characterized pathologically by amyloid plaques, composed of aggregated 
amyloid beta (Aβ) peptide, and neurofibrillary tangles, comprised of 
hyperphosphorylated tau (4, 239). Vascular cognitive impairment and dementia 
(VCID) is the second most common form of dementia and results from 
disruptions in blood flow to the brain such as stroke, hypoperfusion of the brain, 
microhemorrhages, and vasogenic edema (240). VCID and AD are not mutually 
exclusive though; it is estimated that 40% of AD patients also have some form of 
VCID (59-61, 241).  
The most common hypothesis for the progression of AD is the amyloid 
cascade hypothesis, which states that Aβ aggregation leads to 
hyperphosphorylation of tau and tangle formation, which then leads to 
neurodegeneration (17, 18). As the leading hypothesis for the progression of AD, 
amyloid deposition and brain Aβ have become popular targets for many AD 
therapeutics. Immunotherapy targeting Aβ has been one of the most promising 
therapeutic interventions for AD since its initial report in 1999 (29). Anti-Aβ 
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immunotherapy uses antibodies targeting Aβ to reduce brain Aβ burden. 
Proposed mechanisms of action include microglial recruitment and Fcγ receptor 
mediated phagocytosis (36, 38), catalytic disaggregation and solublization (47), 
and the peripheral sink mechanism (37). The relative contribution of each 
mechanism on the overall efficacy of the antibody likely relies on the isotype and 
epitope of the specific antibody (36, 38, 48, 49, 242).  
While preclinical mouse model studies have repeatedly demonstrated 
significant efficacy of anti-Aβ immunotherapy, both in reducing Aβ burden and 
improving cognition (29, 31, 43, 243), the clinical trials have remained 
underwhelming, failing to meet primary endpoints for efficacy in a number of trials 
to date (46, 244). While there has been discussion in the field that one reason for 
the lack of efficacy in clinical trials is that the disease is too advanced, we 
hypothesize that one reason for the lack of efficacy in clinical trials is the co-
morbidity of other dementia-causing pathologies, such as VCID, as well as AD 
pathology.  
To test our hypothesis, we are using our recently developed mouse model 
of Aβ deposition co-morbid with VCID (APP/PS1 + HHcy) (204), which develops 
additive cognitive deficits and redistribution of amyloid favoring the deposition of 
cerebral amyloid angiopathy (CAA). Using our co-morbidity model, we 
administered 3D6, an anti-Aβ antibody, or IgG2a, a control antibody to test 
passive immunotherapy efficacy in a mixed dementia mouse model. We found 
that there was no cognitive benefit of immunotherapy in our co-morbidity model 
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despite comparable reductions in total Aβ burden. This was accompanied by a 
reduced immune response to the immunotherapy.  
Methods 
 
Animals: Female and male wildtype (WT) and APP/PS1 mice (C57BL/6 mice 
carrying human APPSwe and PS1-dE9 mutations) (170) were bred in house and 
aged 9 months. Thirty-five WT mice and thirty-three APP/PS1 mice were placed 
on either a diet with low levels of folate, vitamins B6 and B12 and enriched with 
methionine (HHcy study group) or a control diet with normal levels of folate, 
vitamins B6 and B12 and methionine (control study group). The HHcy diet was 
Harlan Teklad TD97345 and the control diet was Harlan Teklad 5001 C (both 
from Harlan Laboratories, Madison, WI, USA). Once mice had received the diet 
for 3 months, they began weekly intraperitoneal (IP) injections of either 3D6 or 
IgG2a at 10mg/kg (Eli Lilly, Indianapolis, IN, USA) for 3 months. The anti-Aβ 
antibody 3D6, which is an IgG2b isotype, binds to both soluble and insoluble Aβ 
at the extreme amino terminus (Aβ1-5) (41, 245). Although the control antibody 
and the anti-Aβ antibody are not similar isotypes, they both have similar immune 
functions with IgG2a actually having a higher affinity for FcγR1 (246). Control 
IgG2a antibodies have been shown to have no effect on Aβ burden (245). This 
study was approved by the University of Kentucky Institutional Animal Care and 
Use Committee and conformed to the National Institutes of Health Guide for the 
Care and Use of Animals in Research. Behavioral testing and magnetic 
resonance imaging was also performed and an experimental timeline with the 
number of animals per group is shown in Figure 4.1A and B.  
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Behavior testing: Radial arm water maze (RAWM) testing was performed at the 
University of Kentucky Rodent Behavior Core. The two-day RAWM was carried 
out as previously described (247). Briefly, a six-arm maze was submerged in a 
pool of water with a goal platform placed at the end of one arm. Each mouse was 
subjected to 15 trials each day with the mouse starting in a different arm for each 
trial and the goal platform remaining in the same arm. The number of errors (the 
number of incorrect arm entries) was counted over a 60 second period. Errors 
were averaged for 3 trials resulting in ten blocks over the two days. Blocks 1-5 
comprise Day 1 trials while blocks 6-10 comprise Day 2 trials.  
Magnetic resonance imaging: A subset of study mice were imaged by T2* 
magnetic resonance imaging (MRI). Three to four mice from each group were 
imaged 3 months after starting diet but before beginning IP antibody injections, 
again half way through IP antibody injections, and a third time immediately before 
tissue collection. Mice were imaged with a 7-T Bruker ClinScan MRI system 
(Bruker, Billerica, MA, USA) with an MRI CryoProbe, delivering 2.5 times the 
signal to noise of a standard room temperature radiofrequency coil, located at the 
Magnetic Resonance Imaging and Spectroscopy Center at the University of 
Kentucky. Fourteen coronal slices were acquired with a FLASH sequence with a 
TR 165ms, TE 15.3ms, 25 degree flip angle, 448 x 448 matrix, 0.4 mm thick, 
20% gap, 0.033 mm x 0.033 mm resolution, 10 averages, and TA 24 minutes. 
Mice were anesthetized with 1.3% isoflorane using an MRI compatible vaporizer. 
They were then positioned prone and held in place on the scanning bed using 
tooth and ear bars. The animals were maintained at 37° with a water heated 
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scanning bed. Body temperature, heart, and respiration rates were monitored. 
T2* MRI images were analyzed by one blinded investigator who identified 
abnormalities that resembled hemorrhagic infarcts. These infarcts were counted 
and this number was normalized to the number of images counted to provide a 
per section count. 
Tissue processing and histology: After a lethal injection of Beuthanasia-D, 
blood was collected for plasma and mice were perfused intracardially with 25mL 
normal saline. Brains were removed rapidly and bisected in the midsaggital plane 
with the left side being immersion fixed in 4% paraformaldehyde for 24 hours. 
The right side was dissected with the frontal cortex and hippocampus flash 
frozen in liquid nitrogen and then stored at -80°C. The left hemibrain was passed 
through a series of 10, 20 and 30% sucrose solutions for cryoprotection before 
sectioning. Using a sliding microtome, 25µm frozen horizontal sections were 
collected and stored free floating in 1xDPBS containing sodium azide at 4°C.  
Eight sections spaced 600µm apart were selected for free floating 
immunohistochemistry for CD11b (rat monoclonal, AbD Serotec, Raleigh, NC, 
USA, 1:1000 dilution) and total Aβ (rabbit polyclonal Aβ1-16, Life Technologies, 
Carlsbad, CA, USA, 1:3000 dilution). Immunohistochemistry was performed as 
previously described (248). Stained sections were mounted, air dried overnight, 
dehydrated and coverslipped in DPX (Electron Microscopy Sciences, Hatfield, 
PA, USA). Analysis was performed by measuring the percent area occupied by 
positive immunostain using the Nikon Elements AR image analysis system 
(Melville, NY, USA) as described previously (94).  
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Eight sections spaced 600µm apart were mounted on slides and stained 
for Congo red and Prussian blue as previously described (43, 249). Neutral red 
was used as a counterstain for Prussian blue. Congo red analysis was performed 
using the ZEISS Axio Scan.Z1 Slide Scanner (Carl Zeiss Microscopy, Germany) 
and the Nikon Elements AR image analysis system (Melville, NY, USA).  
Plasma was analyzed for total homocysteine by the Clinical Laboratory of 
the University of Kentucky Hospital Laboratories.  
Aβ ELISA: Biochemical analysis of Aβ levels was performed as previously 
described (250). Briefly soluble protein was extracted from the right frontal cortex 
using PBS with complete protease and phosphatase inhibitor (Pierce 
Biotechnology Inc., Rockford, Il, USA). After centrifugation, the supernatant was 
labeled the “soluble” extract and the pellet was homogenized in 70% formic acid. 
After centrifugation and neutralization with 1M Tris-HCl, the supernatant was 
labeled the “insoluble” extract. Protein concentrations were determined using the 
BCA protein assay kit (Pierce Biotechnology, Inc., Rockford, Il, USA). The Meso-
Scale Discovery multiplex ELISA system was used to measure Aβ1-38, Aβ1-40, and 
Aβ1-42 levels in the soluble and insoluble extracts (V-PLEX Aβ Peptide Panel 1 
(6E10) Kit; MSD, Gaithersburg, MD, USA).  
Quantitative real-time PCR: RNA was extracted from the right hippocampus 
using the E.Z.N.A. Total RNA kit (Omega Bio-Tek, Norcross, GA, USA) 
according to the manufacturer’s instructions. RNA was quantified using the 
Biospec nano spectrophotometer (Shimaduz, Japan). cDNA was produced using 
the cDNA High Capacity kit (ThermoFisher, Grand Island, NY, USA) according to 
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the manufacturer’s instructions. Real-time PCR was performed using the Fast 
TaqMan Gene Expression assay (ThermoFisher, Grand Island, NY, USA). In 
each well of a 96-well plate, 0.5µL cDNA (100ng, based on the RNA 
concentrations) was diluted with 6.5µL RNase-free water. One microliter of the 
appropriate gene probe was added along with 10µL of Fast TaqMan to each well. 
Target amplification was performed using the ViiA7 (Applied Biosystems, Grand 
Island, NY, USA). All genes were normalized to 18S rRNA and the fold change 
was determined using the –∆∆Ct method. Results from all APP/PS1 mice were 
compared to APP/PS1 mice on control diet with IgG2a treatment. Table 2.1 
shows the genes tested along with their PMID and Taqman ID.  
Analysis: Data are presented as mean ± SEM. Statistical analysis was 
performed using the JMP statistical analysis software program (SAS Institute, 
Cary, NC, USA). Radial arm water maze data were analyzed by repeated-
measures analysis of variance (ANOVA). We also performed student’s t-test on 
individual block data for the radial arm water maze analysis. For other data, one-
way ANOVA and student’s t-test were performed. Statistical significance was 
assigned when the P-value was <0.05. 
Results 
Administration of a diet deficient in folate, vitamins B6 and B12 and 
enriched in methionine to 9-month-old WT and APP/PS1 mice for 6 months 
resulted in elevated plasma homocysteine levels as shown in Figure 4.1C. In 
C57BL/6 mice, a level of homocysteine between 5 and 12µmol/L is considered 
normal. Elevated levels of homocysteine can be categorized as mild, with levels 
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between 12 and 30µmol/L, moderate, with levels between 30 and 100µmol/L and 
severe, with levels above 100µmol/L. The mice on control diet had plasma HHcy 
levels below the detection range of the clinical assay. Mice on our normal house 
chow also have levels below the detection range showing that mice on the 
control diet have a normal level of homocysteine. Plasma homocysteine levels in 
our mice on the HHcy diet reached moderate to severe levels ranging from 67-
145µmol/L in all cases, thus inducing hyperhomocysteinemia. Due to the high 
variability, the only comparison showing significant differences was between the 
APP/PS1 mice on control diet receiving 3D6 and the APP/PS1 mice on the HHcy 
diet receiving the 3D6 treatment (Figure 4.1C). 
 We performed the two-day radial arm water maze to identify changes in 
spatial memory. Over the two days of testing, the WT mice on control diet with 
IgG2a treatment learned the task. They started the task making an average of 
three errors in the first block and ended with less than one error in the last block 
(Figure 4.2A). WT mice on the HHcy diet had similar cognitive deficits as 
previously reported (203), with no effect of 3D6 or IgG2a (Figure 4.2A). APP/PS1 
mice on control diet with IgG2a treatment did not learn the task over the two days 
and were significantly impaired compared to WT mice on control diet with IgG2a 
treatment by block 10, as expected from APP/PS1 mice of this age (Figure 4.2B). 
APP/PS1 mice on control diet with 3D6 treatment began the task with an average 
of about 4 errors in block 1 and were making less than one error by the last 
block, indicating that they did learn the task and they were indistinguishable from 
the WT mice on control diet with IgG2a treatment. APP/PS1 mice on the HHcy 
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diet with either IgG2a or 3D6 treatment did not learn the task, making a similar 
amount of errors in the first and last block. At the end of day 2, they made 
significantly more errors than the WT mice on control diet with IgG2a treatment 
or the APP/PS1 mice on control diet with 3D6 treatment as shown in the block 10 
data in Figure 4.2D. The APP/PS1/HHcy mice did not show the additive effects 
we have previously reported in this mixed pathology APP/PS1/HHcy mouse 
(204), however, as can be seen from the learning curve of the APP/PS1 mice, 
there was essentially a “ceiling effect”, likely due to the older age of the mice in 
the current study. Therefore, we were unable to detect any potential worsening 
resulting from the HHcy component.  
 Total Aβ immunohistochemistry was used to determine the efficacy of an 
anti-Aβ immunotherapy to reduce Aβ levels in our co-morbidity model. In the 
frontal cortex, total Aβ was significantly reduced in the APP/PS1 mice on control 
diet with 3D6 treatment compared to APP/PS1 mice on control diet with IgG2a 
treatment (Figure 4.3E). Levels were slightly reduced in the APP/PS1 mice on 
the HHcy diet with 3D6 treatment but did not reach significance. In the 
hippocampus, total Aβ was significantly reduced in both the APP/PS1 mice on 
control and HHcy diet with 3D6 treatment compared to APP/PS1 mice on control 
diet with IgG2a treatment (Figure 4.3A-E). When APP/PS1 mice on HHcy diet 
with control antibody were compared to APP/PS1 mice on HHcy diet with 3D6 
antibody, there was no significant difference. Biochemical levels of Aβ were also 
measured and are shown in Figure 4.3F. No significant differences were found 
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among any of the groups, likely due to the high variation among the individual 
samples. 
Congo red analysis showed that amyloid levels were reduced in the 
parenchyma following 3D6 treatment in APP/PS1 mice on both the control diet 
and the HHcy diet when they were compared to APP/PS1 mice on control diet 
with control antibody (Figure 4.4E). This effect was more pronounced in the 
hippocampus than the frontal cortex. In contrast to the total amyloid reductions, 
the APP/PS1 mice on the HHcy diet showed significant increases in CAA relative 
to the APP/PS1 mice on control diet. This effect was not influenced by 3D6 
administration, replicating our previous report that HHcy leads to redistribution of 
amyloid to the vasculature (204). 3D6 administration in the APP/PS1 mice on 
control diet caused a modest increase in CAA relative to control antibody.  
We used T2* MRI imaging to detect microhemorrhages as described 
previously (203). At the first imaging session, 3 months into the diet but 
immediately prior to the initiation of anti-Aβ immunotherapy, we found modest, 
non-significant increases in microhemorrhages resulting from the administration 
of the HHcy inducing diet, consistent with our previous reports (Figure 4.5B). Six 
weeks into immunotherapy treatment, we found that there were significant 
increases in microhemorrhages resulting from the HHcy inducing diet; however, 
the control IgG2a and 3D6 groups were still comparable. In contrast, 12 weeks 
into immunotherapy treatment, immediately prior to cognitive testing and tissue 
harvest, we found that microhemorrhage numbers were significantly greater in 
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the APP/PS1 mice on the HHcy or control diet receiving 3D6 antibody than either 
the APP/PS1 mice on control diet or the HHcy diet receiving IgG2a treatment.  
Prussian blue histological analysis of microhemorrhages showed a 
significant increase in the number of microhemorrhages in each of the groups 
compared to APP/PS1 mice on control diet with IgG2a treatment (Figure 4.6B). 
The APP/PS1 mice on the HHcy diet with IgG2a treatment also had significantly 
more microhemorrhages when compared to the 3D6 treated APP/PS1 mice on 
control diet. Also, the APP/PS1 mice on the HHcy diet with 3D6 treatment had a 
significant increase in microhemorrhages compared to all the other groups. The 
majority of microhemorrhages were located in the parietal and occipital cortex 
with no differences in location between any of the groups. Images of a positive 
Prussian microhemorrhage are shown in Figure 4.6A.  
One of the proposed mechanisms for anti-Aβ immunotherapy’s reduction 
of Aβ involves activation of microglia leading to phagocytosis of Aβ. We 
performed immunohistochemistry for CD11b, which labels both activated and 
resting microglia, in order to determine if there was an increase in total microglia. 
In both the frontal cortex and the hippocampus, CD11b was slightly increased in 
the APP/PS1 mice on control diet with 3D6 treatment compared to the APP/PS1 
mice on control diet with IgG2a treatment (Figure 4.7E), but this was not 
significant. CD11b staining was significantly reduced in the frontal cortex in the 
APP/PS1 mice on the HHcy diet with 3D6 treatment compared to the APP/PS1 
mice on control diet with 3D6 treatment. In the hippocampus, the APP/PS1 mice 
on the HHcy diet with IgG2a or 3D6 treatment had significantly reduced levels of 
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CD11b staining compared to the APP/PS1 mice on control diet with 3D6 
treatment (Figure 4.7A-E). The amount of CD11b staining was also slightly 
reduced in the APP/PS1 mice on the HHcy diet with IgG2a or 3D6 treatment 
compared to APP/PS1 mice on control diet with IgG2a treatment. 
Using several genetic markers specific to a pro-inflammatory, wound 
healing/repair or immune complex mediated macrophage phenotype (251, 252), 
we characterized the neuroinflammatory response. The data in Figure 4.8 is 
shown as a fold change from the APP/PS1 mice on control diet with IgG2a 
treatment. The APP/PS1 mice on control diet with 3D6 treatment showed a 
significant increase in several pro-inflammatory markers (specifically IL1β and 
TNFα) and increases in several immune complex mediated genes (FcγR1 and 
FcγR3) (Figure 4.8A and C). The APP/PS1 mice on the HHcy diet with IgG2a 
treatment showed elevations in several wound healing/repair genes (ARG1) 
(Figure 4.8B). The APP/PS1 mice on the HHcy diet with 3D6 treatment only 
showed significant changes in some immune complex mediated genes (FcγR1 
and FcγR3) (Figure 4.8C). There were also several significant increases in the 
expression of the MMP2 and MMP9 system markers as shown in Figure 4.8D. 
The APP/PS1 mice on control diet with 3D6 treatment showed a significant 
increase in MMP2, MMP3 and MMP9. The APP/PS1 mice on the HHcy diet 
showed an increase in MMP9 expression as well.   
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Figure 4.1 Experimental setup. A) Mice were 9 months old when they began 
either the control or HHcy diet. After being on diet for 3 months, mice began a 3-
month treatment of weekly IP injections of 3D6 or IgG2a at 10mg/kg. MRI was 
performed 3 months after starting the diet but before IP injection treatment, half 
way through treatment and immediately before tissue collection. The two-day 
radial arm water maze was also performed before tissue collection. B) Number of 
animals per experimental group. C) Quantification of plasma total homocysteine 
levels.  
 99 
 
 
 
 
Figure 4.2 3D6 treatment does not improve cognition in APP/PS1 mice on 
the HHcy diet. Two-day radial arm water maze data is shown for WT mice (A) 
and APP/PS1 mice (B). The mean number of errors per trial was calculated for 
each block (each block is the average of three trials). * indicates P<0.05 and ** 
indicates P<0.01 by one-way ANOVA with all groups on each graph. Block 10 
data is graphed for the WT mice (C) and the APP/PS1 mice (D). ** indicates 
P<0.01 compared to WT, control, IgG2a and WT, control, 3D6 for C and P<0.01 
compared to WT, control, IgG2a and APP/PS1, control, 3D6 for D. 
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Figure 4.3 Total Aβ is reduced by 3D6 treatment. Representative images of 
Aβ staining in the hippocampus of APP/PS1, control, IgG2a (A), APP/PS1, 
control, 3D6 (B), APP/PS1, HHcy, IgG2a (C), and APP/PS1, HHcy, 3D6 (D) are 
shown. The cornu ammonis (CA) 1, CA3 and dentate gyrus (DG) are labeled in A 
for orientation. Scale bar in A = 120µm. E) Quantification of percent positive stain 
in the frontal cortex and hippocampus. * indicates P<0.05 compared to APP/PS1, 
control, IgG2a. F) Biochemical quantification of soluble and insoluble Aβ1-38, Aβ1-
40 and Aβ1-42 ± SEM. 
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Figure 4.4 HHcy redistributes amyloid to the vasculature. Representative 
images of Congo red staining in the hippocampus of APP/PS1, control, IgG2a 
(A), APP/PS1, control, 3D6 (B), APP/PS1, HHcy, IgG2a (C), and APP/PS1, 
HHcy, 3D6 (D) are shown. The CA1, CA3 and DG are labeled in A for 
orientation. Scale bar in A = 200µm. Representative images of Congo red 
staining in the cortex of APP/PS1, control, IgG2a (E), APP/PS1, control, 3D6 (F), 
APP/PS1, HHcy, IgG2a (G), and APP/PS1, HHcy, 3D6 (H) are shown. Scale bar 
in E = 50µm. Black arrows indicate Congo staining around a vessel (CAA).  I) 
Quantification of percent positive stain in the frontal cortex and hippocampus. * 
indicates P<0.05, ** indicates P<0.01 compared to APP/PS1, control, IgG2a. 
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Figure 4.5 3D6 increases MRI detected microhemorrhages. A) 
Representative T2* images of 3D6 treated mice. Arrows indicate a 
microhemorrhage. B) Quantification of the number of microhemorrhages per 
section over the 3 imaging sessions. * indicates P<0.05, ** indicates P<0.01 
compared to APP/PS1, control, IgG2a. 
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Figure 4.6 3D6 and HHcy increase Prussian blue detected 
microhemorrhages. A) Representative images of Prussian blue positive 
microhemorrhages in the frontal cortex. Scale bar = 120µm. B) Quantification of 
the mean number of microhemorrhages per section. ** indicates P<0.01 
compared to APP/PS1, control, IgG2a. Black bars represent significant 
differences between connecting groups. 
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Figure 4.7 CD11b staining is decreased in the HHcy groups. Representative 
images of CD11b staining in the hippocampus of APP/PS1, control, IgG2a (A), 
APP/PS1, control, 3D6 (B), APP/PS1, HHcy, IgG2a (C), and APP/PS1, HHcy, 
3D6 (D) are shown. The CA1, CA3 and DG are labeled in A for orientation. Scale 
bar in A = 120µm. Higher magnification images of CD11b staining in the dentate 
gyrus of APP/PS1, control, IgG2a (E), APP/PS1, control, 3D6 (F), APP/PS1, 
HHcy, IgG2a (G), and APP/PS1, HHcy, 3D6 (H) are shown. Scale bar in E = 
50µm. I) Quantification of percent positive stain in the frontal cortex and 
hippocampus. 
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Figure 4.8 HHcy reduced inflammatory markers and increased the MMP 
system markers in both the IgG2a and 3D6 groups. Data are shown as a fold 
change from APP/PS1, control, IgG2a. Relative gene expression for pro-
inflammatory markers (A), would healing/repair markers (B) immune complex 
mediated markers (C) and MMP2 and MMP9 system markers (D). * indicates 
P<0.05, ** indicates P<0.01 compared to APP/PS1, control, IgG2a.  
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Table 4.1: Genes for RT-PCR. 
 
Gene of interest PMID Taqman ID 
IL1β NM_008361.3 Mm.222830 
TNFα NM_013693.3 Mm.1293 
IL12a NM_008351.2 Mm.103783 
IL12b NM_008352.2 Mm.239707 
Marco NM_010766.2 Mm.1856 
IL10 NM_010548.2 Mm.874 
ARG1 NM_007482.3 Mm.154144 
YM1 NM_009892.2 Mm.387173 
Fizz NM_020509.3 Mm.441868 
IL1Ra NM_031167.5 Mm.882 
CD86 NM_019388.3 Mm.1452 
FcγR1 NM_010186.5 Mm.150 
FcγR3 NM_010188.5 Mm.22119 
TGF1β NM_011577.1 Mm.248380 
MRC1 NM_008625.2 Mm.2019 
MMP14 NM_008608.3 Mm.280175 
MMP2 NM_008610.2 Mm.29564 
TIMP2 NM_011594.3 Mm.206505 
MMP3 NM_010809.1 Mm.4993 
MMP9 NM_013599.3 Mm.4406 
TIMP1 NM_001044384.1 Mm.8245 
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Discussion  
 While AD is the most common form of dementia, VCID is the second most 
common and it is estimated that 40% of AD patients also have some form of 
VCID (59-61, 241). One promising therapeutic for AD is anti-Aβ immunotherapy, 
which uses antibodies against Aβ to clear it from the brain. In mice, anti-Aβ 
immunotherapy significantly reduced Aβ levels and improved cognitive outcomes 
(29, 31, 43, 243); however, in clinical trials, anti-Aβ immunotherapy failed to 
reach primary cognitive outcomes in several different clinical trials (46, 244). In 
addition, anti-Aβ immunotherapy has been associated with adverse 
cerebrovascular events. In mice, these manifested as microhemorrhages (40, 41, 
43), while in clinical trials, it presented as vasogenic edema, detected using MRI 
imaging techniques. These adverse events were termed amyloid related imaging 
abnormalities (ARIA). Under this term, they were called ARIA-H (hemorrhagic) 
and ARIA-E (vasogenic edema) (253). We hypothesized that one potential 
reason the anti-Aβ immunotherapy clinical trials were unsuccessful, both 
cognitively and with respect to the ARIA, was due to this high percent of VCID 
co-morbidity in the AD population. We used our unique model of VCID-amyloid 
co-morbidity to test this hypothesis.  
We placed 9 month old WT and APP/PS1 mice on either a control diet or 
a diet that induces HHcy. Our lab has previously shown that a diet deficient in 
vitamins B6 and B12 and folate and enriched in methionine induces HHcy (204), 
which is a risk factor for VCID and cardiovascular disease (185, 186). After being 
placed on the diet for 3 months, the mice then received IP injections of either 
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IgG2a or 3D6 for another 3 months. While we found that treatment of our co-
morbidity model with 3D6 resulted in decreased total Aβ levels, there was no 
cognitive benefit of the anti-Aβ immunotherapy in our AD/VCID mice. Further, 
microhemorrhages were increased by 3D6 in the APP/PS1 on control diet, but 
further increased in an additive fashion when 3D6 was administered to the 
APP/PS1/HHcy mice.   
Total Aβ deposition, which is mostly diffuse deposition, was reduced in the 
3D6 treated animals, both APP/PS1 and APP/PS1/HHcy compared to APP/PS1 
controls. Total Aβ deposition in the APP/PS1 mice on HHcy diet with 3D6 were 
not significantly different compared to APP/PS1 mice on HHcy diet with IgG2a, 
although did show trends for reduction.  We found that amyloid distribution was 
altered when we examined Congo red staining. When we looked at parenchymal 
versus vascular Congophilic amyloid deposition using our previously described 
method (249), we saw that the HHcy diet resulted in an apparent redistribution of 
the amyloid to the vasculature, as CAA, replicating our previous finding (204). 
We did not find that 3D6 altered this outcome. Interestingly, despite the 
comparable levels of CAA between the 3D6 treated and control antibody treated 
APP/PS1/HHcy mice, microhemorrhages were significantly increased in the 3D6 
treated mice, indicating that the microhemorrhages do not occur simply due to 
the presence of CAA, but that the anti-Aβ antibody causes a local reaction at the 
vessel, resulting in leakage.  
We have previously shown that MMP activation, in particular MMP9, is 
associated with tight junction breakdown and microhemorrhages, both in 
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response to immunotherapy (254) and in the HHcy model (203, 204). MMP9 has 
been implicated in cerebrovascular injury including hemorrhagic transformation 
after stroke and microhemorrhage occurrence in CAA (130, 144). In our study, 
both 3D6 and HHcy significantly increased gene expression of MMP9, similar to 
previous studies. MMP3, an activator of MMP9, was also increased in the 3D6 
treated control APP/PS1 mice.  
It is unclear what mechanism is responsible for the increased MMP9 and 
MMP3 in the current study. MMP9 and MMP3 can be activated by pro-
inflammatory cytokines such as IL1β and TNFα (113, 114). As a result of this 
literature and our previous data (203, 204), we explored neuroinflammation in the 
current study. Our findings were intriguing, and suggest that the immunotherapy 
did not result in an overt inflammatory response by the microglia. TNFα and IL1β 
were only significantly increased in the 3D6 treated control APP/PS1 mice and 
not in either of the HHcy treated groups. In fact, both the HHcy treated groups 
had a slight reduction in CD11b staining and did not show any changes in the 
majority of markers for any of the neuroinflammatory states. In our previous 
study, we showed that the APP/PS1 mice on the HHcy diet had a 
neuroinflammatory shift from wound healing and repair to a pro-inflammatory 
state (204). Due to the older age of the mice in this study (15 months rather than 
12 months), and the addition of a treatment arm, the mice could have progressed 
past this neuroinflammatory shift. Unfortunately, we are only able to assess the 
changes post-mortem, and thus cannot know what changes preceded those 
reported here. Based on our data, we hypothesize that either there is a decrease 
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in the numbers of microglial cells, or the microglia could be senescent. The 
constant activation from high Aβ levels, long-term HHcy, and weekly 
administration of antibodies could force the microglia into senescence, resulting 
in the decreased CD11b staining and lack of immune activation. It is also 
possible that the decreased CD11b staining, which also labels other myeloid 
cells like monocytes, could also result from HHcy suppression of infiltration of 
peripheral cells, although this seems unlikely since the HHcy diet results in a 
microhemorrhage induction. Therefore, while MMP9 may be responsible for the 
tight junction breakdown leading to microhemorrhages, pro-inflammatory 
cytokines do not seem to be the stimulating factor in the current study. 
 Previous anti-Aβ immunotherapy studies have shown that the use of anti-
Aβ antibodies significantly improves cognitive outcomes in mice (29, 31, 43, 
243). While we saw that 3D6 treatment significantly reduced the number of errors 
APP/PS1 mice on control diet made making then indistinguishable from the WT 
controls, the presence of HHcy impeded those benefits. The APP/PS1 mice on 
the HHcy diet with 3D6 treatment did not benefit cognitively from the anti-Aβ 
immunotherapy. In fact, they were not significantly different from the APP/PS1 
mice on the HHcy diet with IgG2a treatment by the end of the second day. This 
lack of cognitive benefits could be due to the increase in the number of 
microhemorrhages seen in the 3D6 treated HHcy mice compared to the 3D6 or 
HHcy controls, or the increased levels of CAA. We cannot rule out that there may 
have been a benefit to the APP/PS1/HHcy that was undetected in our selected 
behavioral task due to wildtype HHcy mice also reaching a ceiling effect. Future 
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studies will try to develop more sensitive behavioral tasks that may discriminate 
these effects. Despite the Aβ reductions in the APP/PS1/HHcy mice, the increase 
in vascular damage and leakage appears to negate any cognitive benefits of 
clearing the Aβ. This suggests that anti-Aβ immunotherapy in patients with VCID 
co-morbid with AD may be ineffective with respect to function outcomes. 
Prescreening subjects for cerebrovascular pathologies prior to enrollment in anti-
Aβ immunotherapy clinical trials may reduce the adverse cerebrovascular events 
seen during treatment and this could result in significantly improved cognitive 
outcomes. Although anti-Aβ immunotherapy trials are moving towards treatment 
of prodromal AD, VCID still remains a concern since the immunotherapy could 
hasten any vascular dysfunction that is present but asymptomatic.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 115 
Chapter 5 
Discussion 
 The chapter 5 discussion has been separated into the main themes of the 
entire dissertation. First, it begins with a brief summary of chapters 2-4, and then 
moves into a discussion on neuroinflammation and the details tying together 
chapters 2-4. Then, the discussion moves on to how each chapter provides 
crucial information regarding the vascular contributions to dementia. Finally, the 
last two sections discuss the larger translational implications of the three studies 
as well as future directions for this research. 
Summary 
Using an adeno-associated viral vector for long-term expression of IFNγ in 
Aβ depositing mice, a pro-inflammatory response was induced at 4 months, 
which transitioned to a mixed inflammatory phenotype by 6 months. While there 
was no change in Aβ deposition at 4 months, there was a significant increase 
after the transition to a mixed phenotype at 6 months. This suggests that the 
wound healing and repair inflammatory phenotype increased Aβ deposition and, 
therefore, disease progression. There are several studies that have attempted to 
determine the effect of a pro-inflammatory versus an anti-inflammatory 
phenotype on Aβ deposition; however, these were all acute experiments, only 
lasting up to a month and a half while our study induced a chronic pro-
inflammatory phenotype.  
   Hyperhomocysteinemia is a risk factor for vascular disease as well as 
VCID (184-187), but little is known about the effects of high levels of 
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homocysteine on the individual cell types of the brain, especially microglia. We 
showed that treatment of microglia with high levels of homocysteine resulted in a 
pro-inflammatory response at 48 hours, but this transitioned into an anti-
inflammatory phenotype by 72 hours. HHcy’s effects on other cell types included 
a reduction in several potassium channels in astrocytes, changes in tight junction 
proteins in endothelial cells, and increases in kinases and phosphatases in 
neurons. These gene changes can be used as possible biomarkers for VCID 
patients as well as therapeutic targets. 
 While there is still much to be learned about AD and VCID as individual 
dementias, it is also crucial to study the co-morbidity of these two dementias, 
especially in regard to therapeutics. Because a large percentage of AD patients 
have co-morbid cerebrovascular pathologies, this could interfere with the efficacy 
of therapeutics targeting AD pathologies. We have shown that when Aβ 
depositing mice are placed on a diet that induces HHcy and then treated with an 
anti-Aβ antibody, there is significant Aβ clearance but no cognitive benefits. 
Interestingly, these mice also have a significant decrease in microglial staining 
and a limited inflammatory response.   
Neuroinflammation 
It is well known that inflammation and microglia play a role in the brain and 
in AD; however, this role remains unclear in AD. Initially, the presence of 
activated microglia was termed inflammation. Later, it was realized that microglia 
can be “classically” or “alternatively” activated. Using peripheral macrophage 
phenotypic nomenclature, these activation states were then termed M1 and M2. 
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Today, the neuroinflammation field has switched to pro-inflammatory and anti-
inflammatory to describe the inflammatory phenotypes of the brain. Several 
studies have shown that microglia are capable of surrounding Aβ plaques and 
can phagocytose Aβ (255, 256). Microglia can also be stimulated by a variety of 
substances to produce an inflammatory phenotype in the brain. We have shown 
that high levels of homocysteine induced an initial pro-inflammatory phenotype in 
vitro and this remained true in wildtype mice with HHcy (203). This inflammatory 
phenotype can then affect Aβ levels. For example, short-term induction of a pro-
inflammatory phenotype via LPS or TNFα led to Aβ clearance (83, 216). On the 
other hand, short-term induction of an anti-inflammatory phenotype exacerbated 
Aβ deposition (257). A recent study inducing a long-term anti-inflammatory 
phenotype via IL-10 showed a significant increase in Aβ deposition and 
worsened cognitive behavior (258). We have shown that long-term expression of 
IFNγ initially induced a pro-inflammatory phenotype, which did not affect Aβ 
levels. However, when the inflammatory phenotype switched to a mixed 
inflammatory phenotype by including several anti-inflammatory markers, we saw 
a significant increase in Aβ deposition. 
When HHcy is induced long-term in Aβ depositing mice, it induced a switch 
from a wound healing and repair phenotype to a pro-inflammatory phenotype, 
similar to what we have shown in vitro (204). Again, this long-term pro-
inflammatory phenotype did not affect total levels of Aβ; however, there was a 
redistribution of the amyloid from the parenchyma to the vasculature (204). This 
is somewhat similar to what we saw when anti-Aβ antibodies were used to clear 
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Aβ from the brain. The antibodies induced a pro-inflammatory phenotype, which, 
while it did lead to amyloid clearance, also increased CAA levels (39, 43, 243). 
This data suggest that the presence of both HHcy and anti-Aβ antibodies in Aβ 
depositing mice would lead to a significant increase in the pro-inflammatory 
response as well as high levels of CAA. We have shown that APP/PS1 mice with 
HHcy and 3D6 treatment have significant decreases in parenchymal amyloid 
deposition as well as increases in CAA. Interestingly, these mice do not have a 
significant pro-inflammatory response like the APP/PS1 mice on control diet with 
3D6 treatment. In fact, they had a very limited inflammatory response with only a 
small increase in the immune complex mediated markers. While the inflammatory 
phenotype was limited to a small increase in immune complex mediated markers 
by the end of the study, it cannot be ruled out that there was an initial pro-
inflammatory response to the HHcy and 3D6 that contributed to the decrease in 
parenchymal amyloid and increase in CAA. These studies add evidence that an 
anti-inflammatory phenotype increases Aβ deposition while a pro-inflammatory 
phenotype can help clear Aβ, perhaps through vascular clearance methods due 
to the increase in CAA that seems to be associated with the pro-inflammatory 
phenotype.  
Vascular contributions to dementia 
 Our research group has shown that when HHcy is induced in both 
wildtype and APP/PS1 mice, there was a significant increase in 
microhemorrhages (203, 204). There is evidence to show that MMP2 and MMP9 
degrade tight junctions, which can lead to BBB breakdown and microhemorrhage 
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(100, 120). In our mouse models of HHcy, we saw that both MMP2 and MMP9 
had significantly elevated levels of gene expression and activity, suggesting that 
they are responsible for the increased microhemorrhages we observed. The 
APP/PS1 mice on the HHcy diet also showed a redistribution of Aβ leading to an 
increase in CAA and one of the major complications of CAA is intracerebral 
hemorrhage. Both MMP2 and MMP9 have been widely associated with BBB 
disruption and microhemorrhages in CAA. 
Hernandez-Guillamon et al. looked at MMP2 and MMP9 expression in 
CAA patients (259). While plasma MMP2 and MMP9 levels did not discriminate 
between CAA patients and controls, MMP9 and MMP2 levels were higher in the 
hemorrhagic areas of CAA brains. proMMP9 and proMMP2 were significantly 
higher in hemorrhagic areas of patients who died from a fatal hemorrhage. 
MMP9 was mainly found in brain vessels and in neurons around the hemorrhage 
and the contralateral side, while MMP2 was mainly located in medium sized brain 
vessels and capillaries and was more pronounced around the hemorrhagic area. 
MMP2 was also expressed in reactive astrocytes surrounding Aβ affected 
vessels and its expression was clearly associated with the Aβ load in the vessel 
in grade 1 and 2 CAA. Briefly, grade 1 CAA is given when some amyloid deposits 
are found in otherwise normal vessels, grade 2 CAA is used when the vessel 
media is replaced by amyloid, grade 3 CAA is occurs when cracking of the vessel 
wall results in “vessel-within-vessel” appearance and affects at least 50% of the 
circumference of the vessel and finally, grade 4 CAA is given when scarring of 
the wall is observed as well as fibrinoid necrosis and traces of intermingled 
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amyloid deposits (260). In grade 3 CAA lesions, Aβ reactivity was very frequent 
and was found to have MMP2 expression in astrocytes surrounding the lesions. 
Unlike MMP2, MMP9 was found in some isolated macrophages around the grade 
3 CAA lesions. There was some Aβ reactivity in grade 4 CAA lesions and strong 
gliosis was prominent with reactive astrocytes positive for MMP2. MMP9 
expression was similar to grade 3 CAA.  
 Recent evidence suggests that Aβ may contribute to the BBB leakage that 
is associated with CAA. Isolated rat brain microvessels that are exposed to 
increasing concentrations of Aβ1-40 showed a significant decrease in the 
expression of the tight junction proteins claudin-1 and claudin-5 as well as 
increased MMP2 and MMP9 expression (261). Microvessels from 9-month-old 
transgenic APP mice (Tg2576 strain with the Swedish mutation KM670/671NL) 
also showed increased permeability, decreased claudin-1 and claudin-5 as well 
as increased MMP2 and MMP9. Cultured human brain endothelial cells treated 
with Aβ1-40 caused zonula occludens-1 (ZO-1), another tight junction protein that 
forms the BBB, to retreat from the plasma membrane, which in turn decreased 
transendothelial electrical resistance (262). Carrano et al. found decreased 
occludin, claudin-5 and ZO-1 in brain microvessels of postmortem CAA patient 
brain slices (263). These studies have shown that Aβ can contribute to the BBB 
breakdown via increased MMP expression and altered tight junction protein 
localization. 
 The prevailing hypothesis for AD progression is the amyloid hypothesis, 
which, briefly, states that the deposition of Aβ leads to hyperphosphorylation of 
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tau, which in turn leads to neurodegeneration (17). Using this hypothesis to 
develop therapeutics, anti-Aβ immunotherapy became the most promising 
approach for AD. Unfortunately, in clinical trials, vascular adverse events like 
microhemorrhages and vasogenic edema were reported with anti-Aβ treatment 
(46). MMP2 and MMP9 have been implicated in the BBB breakdown that occurs 
after anti-Aβ immunotherapy. In APPSw/NOS2-/- mice that received an active Aβ 
vaccination for 4 months, there was a significant increase in gene expression of 
furin and MMP2 and decreased TIMP2 levels (254). ELISA measurements 
confirmed these qPCR findings. There was also an increase in gene expression 
of MMP3 and a decrease in TIMP1 levels in the actively vaccinated transgenics. 
Protein measurements showed increased MMP3 and MMP9 as well. Within this 
study, gelatin zymography analysis also showed a significant increase in MMP2 
and MMP9 activity in the transgenic mice treated with the active Aβ 
immunotherapy. Robust expression of MMP9 was also found to be associated 
with the vasculature. Similar results were found in passively immunized APPSw 
mice. In vitro studies using BV2 microglial cells showed that Aβ1-42 fibrils 
increased MMP2 and MMP14 gene and protein levels (254). An increase in 
MMP9 and MMP3 occurred when BV2 cells were treated with either an anti-Aβ 
IgG-Aβ or anti-tau IgG-tau immune complex, showing that MMP9 activation 
requires the Fcγ receptor (254).  
 Anti-Aβ antibody studies have not taken into account the high percent of 
co-morbidity patients and the possible consequences on the vasculature in these 
patients (59-61). We showed that mice with Aβ deposition and HHcy with anti-Aβ 
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antibody treatment had a significant increase in microhemorrhages over the 
course of their treatment. They had more microhemorrhages per section than 
both the APP/PS1 mice on control diet with 3D6 and the APP/PS1 mice on the 
HHcy diet with the control antibody by the end of treatment. The co-morbidity 
mice on the immunotherapy also had a significant increase in the amount of CAA 
and the gene expression of MMP9, which could contribute to the increase in 
microhemorrhages.   
 The microhemorrhages seen in these models may also be a direct or 
indirect response to the high levels of homocysteine. In fact, there have been no 
studies to date that have shown what the direct effect of homocysteine is on 
individual cell types. We have shown that HHcy induces significant increases in 
MMP9 gene expression at 48 and 72 hours; however, the source of the MMP9 
was different at each time point, thus providing crucial information that could be 
used for in vivo studies. Coinciding with this increase in MMP9 was an increase 
in pro-inflammatory cytokines from microglia, which could ultimately lead to a 
further increase in MMP9 in vivo due the activation of MMP9 by IL-1β and TNFα. 
While the increase in these pro-inflammatory cytokines and MMP9 could be 
indirect methods of the HHcy induced microhemorrhages, we also showed that 
endothelial cells exposed to high levels of homocysteine have a decrease in 
occludin-1 and collagen type IV at 48 and 72 hours, respectively, showing that 
homocysteine can have a direct effect on the vasculature.  
Overall, Aβ accumulation around the vasculature, anti-Aβ immunotherapy, 
and the presence of high levels of homocysteine separately increased 
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expression of MMP2 and MMP9 and/or altered tight junction expression and 
localization. When combined, they significantly increased the number of 
microhemorrhages compared to groups that did not have all three. This common 
pathway of microhemorrhage occurrence could provide a potential therapeutic 
target for patients with AD and VCID receiving an anti-Aβ immunotherapy. 
Translational implications 
Since vitamins B6, B12 and folate are essential cofactors in the 
metabolism of homocysteine, deficiencies in any of these vitamins can cause 
HHcy. Deficiencies in B vitamins increase with age and are common in the 
elderly population. The prevalence of low vitamin B12 levels can range from 6-
16% in elderly people (264, 265). Due to this high prevalence, clinical trials for B 
vitamin supplementation have been performed. Unfortunately, meta-analyses of 
these clinical trials reveal several issues with data analysis, vitamin levels and 
duration of the studies. In one meta-analysis of B vitamin clinical trials, 7 of the 9 
trials were 12 months or shorter with the shortest one being only one month 
(266). In the trial with the largest number of participants (910), the levels of folic 
acid (0.2 mg) and vitamin B12 (1 µg) were too low to alter plasma homocysteine 
levels. In the FACIT trial (n=818), people in the Netherlands with homocysteine 
levels between 13 and 26 µM but with adequate vitamin B12 levels were given 
0.8 mg/day of folic acid for three years (267). By the end of the trial there was a 
26% reduction in plasma homocysteine compared to the placebo group. The 
placebo group also showed a reduction in sensorimotor speed, information 
processing speed and complex speed but this decline was slowed by the folic 
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acid treatment. In the VITACOG trial, volunteers with mild cognitive impairment 
were placed on a daily combination of folic acid (0.8 mg), vitamin B12 (0.5 mg) 
and vitamin B6 (20 mg) for two years (268). MRI scans at the beginning and end 
of the trial showed a significant slowing of global brain atrophy in the treatment 
group. While the VITACOG trial was not powered to determine changes in 
cognition, one analysis showed cognitive decline in episodic memory, semantic 
memory and global cognition was prevented in people with baseline plasma 
homocysteine above the median (11.3 µM) (269). These clinical trials present 
conflicting data and further trials are needed to determine the benefits of lowering 
homocysteine with B vitamins.  
Another possible therapeutic could be the combination of anti-Aβ 
antibodies with MMP2 and MMP9 inhibitors to reduce the adverse 
cerebrovascular consequences. The majority of MMP inhibition studies for the 
cerebrovasculature have been performed in stroke studies to help reduce the 
severity of hemorrhagic transformation. In one study, inhibition of MMP2 with BB-
1101 resulted in a reduction in edema and BBB permeability at 24 hours after 
stroke (159). This effect did not continue 48 hours after stroke though. In MMP2 
deficient mice, there was a reduced rate of hemorrhagic transformation, smaller 
hemorrhage size and improved neurological function after stroke (156). In vivo 
studies show that inhibition of MMPs after delayed tPA treatment, which is known 
to increase the risk of hemorrhagic transformation in humans, resulted in reduced 
hemorrhage volumes, a reduction in MMP9 activity and an increase in occludin 
and ZO-1 proteins compared to mice treated with tPA alone (270). In vitro studies 
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with GM6001 treatment after tPA treatment with hypoxia and reoxygenation 
resulted in reduced cell damage and an increase in transendothelial electrical 
resistance due to a reduction in degradation of occludin and ZO-1 (270). Similar 
results were shown by Chen et al. where GM6001 treatment significantly reduced 
BBB breakdown and ameliorated brain edema by preventing the decrease in 
occludin and ZO-1 (271). In a model of permanent focal cerebral ischemia, 
treatment with SB-3CT, a gelatinase inhibitor, decreased MMP9 activity, 
decreased basement membrane laminin degradation, prevented pericyte lumen 
from contraction, and protected pericytes and endothelial cells (272). Repeated 
SB-3CT treatment can counteract degradation of neuronal laminin, protect 
neurons from ischemic cell death and ameliorate neurobehavioral outcomes after 
embolic middle cerebral artery occlusion in mice (272). SB-3CT also abolishes 
oxygen glucose deprivation induced reduction of occludin as well as decreases 
Evans blue extravasation and apoptotic cell death after subarachnoid 
hemorrhage (155, 273, 274). A recent clinical trial indicated that minocycline, 
which acts as an anti-inflammatory, could lower plasma MMP9 levels, even at 72 
hours post stroke, and improve neurological outcomes in acute ischemic stroke 
patients treated with tPA (275). However, it is important to note that MMPs have 
also been implicated in the repair functions after cerebral ischemia such as 
neuroblast migration and neuronal plasticity; therefore, MMP inhibition may only 
be beneficial during a short window (112, 276). The success of these MMP 
inhibitors in reducing hemorrhagic transformation after stroke provides evidence 
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that they could be useful in preventing the microhemorrhages seen after anti-Aβ 
antibody treatment in AD and co-morbidity patients. 
While co-treatment with an MMP inhibitor may be a future combination 
therapy, additional studies have been aimed at determining other immune 
modulators to clear Aβ. Recent genome wide association studies have identified 
rare missense variants in triggering receptor expressed on myeloid cells-2 
(TREM2) that were associated with an increased risk of developing AD (277, 
278). TREM2 is a member of the Ig superfamily of receptors and is expressed on 
a number of cells including dendritic cells, osteoclasts, tissue macrophages and 
on microglia. Possible functions of TREM2 include phagocytosis, proliferation, 
cell survival and regulation of inflammatory cytokine production (279-284). Cell 
culture studies show that exogenous expression of TREM2 on CHO or HEK293 
cells increased phagocytic activity (280, 285). In AD, TREM2 has been shown to 
be upregulated within the vicinity of Aβ plaques and TREM2 haplosufficient or 
deficient mice have a significant reduction in the size and number of plaque-
associated microglia (286, 287). This decrease in plaque-associated microgliosis 
was also accompanied by a decrease in the pro-inflammatory cytokines IL-1β 
and TNFα (283, 288). The effect of TREM2 deficiency on Aβ is less clear than its 
effect on microglia. One study showed that TREM2 haploinsufficiency had no 
effect on Aβ in 3 or 7-month-old APP/PS1-21 mice while another showed that 
TREM2 deficient mice had an increase in hippocampal Aβ in 8-month-old 5xFAD 
mice (283, 287). Another study showed a decrease in Aβ deposition in TREM2 
knockout mice (288). Even with these conflicting results, TREM2 could be a 
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promising therapeutic approach outside of anti-Aβ antibodies to help clear Aβ in 
AD patients and may limit the presence of adverse cerebrovascular events seen 
with the anti-Aβ antibodies. It may also prove to be a potential therapeutic for co-
morbidity patients since inflammation plays a role in both AD and VCID. 
Conclusions and future studies 
 It is clear that inflammation plays a crucial role in both AD and VCID as 
well as the co-morbidity of these two dementias. Polarizing the inflammatory 
phenotype to a pro-inflammatory state did not affect AD progression, although 
the natural progression of the inflammatory state to include anti-inflammatory 
markers increased Aβ deposition. High levels of homocysteine induced a pro-
inflammatory phenotype in microglia both in vitro and in vivo and led to increased 
microhemorrhages in vivo. When both Aβ deposition and HHcy are present, an 
anti-Aβ antibody inhibits the inflammatory response and fails to improve 
cognition. Although these studies provide crucial information regarding the role of 
inflammation in AD and VCID, they also raise questions about combination 
therapies for co-morbidity patients. Would the use of a different Alzheimer’s 
therapeutic that doesn’t induce microhemorrhages, such as a β secretase 
inhibitor or possibly activation of TREM2, be sufficient to improve cognition in co-
morbidity patients? Recent research into β secretase inhibitors for AD treatment 
has proven them effective at lowering Aβ levels without increasing 
microhemorrhage occurrence (289). A β secretase inhibitor could be an effective 
treatment in co-morbidity patients if the increase in microhemorrhages due to the 
anti-Aβ immunotherapy hindered any potential cognitive benefits in the co-
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morbidity group. However, if treatment of the underlying VCID is required, a 
combination of an anti-Aβ antibody with B vitamin supplementation might 
improve cognitive decline in patients with AD and HHcy-induced VCID. This 
combination treatment doesn’t take into account the increase in 
microhemorrhages induced by the immunotherapy though, so perhaps a triple 
combination therapy of an anti-Aβ antibody, B vitamin supplementation, and an 
MMP inhibitor may be the best possible approach to reduce microhemorrhage 
occurrence while also clearing Aβ and reducing HHcy. Or to simplify the number 
of treatments, and thus reduce possible off target effects, the most promising 
combination therapy may be a β secretase inhibitor with B vitamin 
supplementation. This would allow for Aβ clearance and reduction of 
homocysteine levels without increasing the number of microhemorrhages.  
 While combination therapies are always a possibility, it may be simpler to 
target a common pathology of AD and VCID. One major overlap, of course, is the 
presence of neuroinflammation, specifically pro-inflammatory markers. 
Unfortunately, several clinical trials using non-steroidal anti-inflammatory drugs 
(NSAID) have not shown any beneficial results (290-292). While an NSAID may 
not be beneficial, a more specific treatment targeting one or more of the pro-
inflammatory signaling pathways may be a more effective treatment. Targeting of 
the TNFα or IL-1β pathway could reduce the pro-inflammatory response as well 
as MMP9 activation and, therefore, reduce microhemorrhage occurrence in both 
AD and VCID. Another possible common target for treatment of co-morbidity 
patients is astrocytic end feet. The astrocytic end foot wraps around arterioles 
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and capillaries in the brain to help maintain ionic and osmotic homeostasis. Our 
research group has recently shown that astrocytic end feet were disrupted in the 
HHcy mouse model, specifically, the anchoring protein Dp71 was decreased and 
there was dislocalization of the aquaporin 4 channel (293). These changes were 
preceded by a pro-inflammatory response and cognitive impairment is only 
present after astrocytic end foot damage occurs. This suggests that the astrocytic 
end foot damage could be caused by the pro-inflammatory response and in turn 
causes the cognitive decline seen in our mouse model of VCID. Astrocytic end 
foot disruption has also been shown in a CAA mouse model as well as in 
humans with CAA (294). Therefore, reducing the damage to astrocytic end feet 
could improve cognition in both AD and VCID patients as well as co-morbidity 
patients.  
 Overall, neuroinflammation has been shown to be a major player in 
several aspects of both AD and VCID as well as their co-morbidity. However, 
there is still much to be learned about the precise mechanisms and 
consequences of neuroinflammation and future studies should focus on 
combination therapies, as well as therapies that target common pathologies in 
order for successful treatment of co-morbidity patients.  
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